Journal of Clinical Psychiatry

Subject Index to Volume 47: January 1986 Through December 1986

Addison's Disease
S. Weir Mitchell's early fictional reference to Addison's disease (letter). May, 278

Adolescents
Mania in adolescence. Dec, 596–599
Psychotropic medication in adolescents: A review. Aug, 400–408

Affective Disorders
A hypergraphic syndrome of automatic writing, affective disorder, and temporal lobe epilepsy in two patients. May, 255–257
Affective disorders and associated psychopathology: A family history study. Apr, 162–169
Brain imaging in the search for biological markers in affective disorder. Oct, Suppl, 7–10
Clinical studies on the phenylethylamine hypothesis of affective disorder: Urine and blood phenylacetic acid and phenylalanine dietary supplements. Feb, 66–70
Effect of carbamazepine on body weight in affectively ill patients. June, 313–314
Is postpsychotic depression a primary affective disorder? (letter with reply). Sept, 482
Mixed cognitive-affective disturbances in the elderly: A new classification. July, 354–356
Pathological gambling and major affective disorder: Preliminary findings. Apr, 201–203
Premenstrual tension syndrome in rapid-cycling bipolar affective disorder. Aug, 415–417
Update on neuroreceptor mechanisms and their implication for the pharmacotherapy of affective disorders. Oct, Suppl, 13–18

Agoraphobia
Agoraphobia: Relative and combined effectiveness of therapist-assisted *in vivo* exposure and imipramine. Mar, 117–122
Current trends in clinical research on panic attacks, agoraphobia, and related anxiety disorders. June, Suppl, 37–39
Treatment of panic disorder and agoraphobia with clonazepam. May, 238–242

Alcohol and Alcoholism
Intravenous drug use in alcoholics. Nov, 551–554
Modulation of ethanol intake by serotonin uptake inhibitors. Apr, Suppl, 16–22
Obsessive-compulsive disorder and alcoholism (letter with reply). Mar, 153
Physostigmine in alcohol withdrawal: A new clinical approach (letter). Oct, 530
The effect of alcoholism on membrane lithium transport. July, 350–353

Alprazolam
Alprazolam as an adjunct to propranolol in anxious outpatients with stable angina pectoris. Jan, 8–11
Alprazolam in the treatment of bulimia (letter). Jan, 49
Alprazolam treatment for panic disorders. June, 301–304
Comparative efficacy of alprazolam, imipramine, and placebo administered once a day in treating depressed patients. July, 357–361
Drug treatment of panic disorder: The comparative efficacy of imipramine, alprazolam, and trazodone. Dec, 580–586
Effect of alprazolam and diazepam on anxiety and panic attacks in panic disorder: A controlled study. Sept, 458–460
Low-sedation potential of buspirone compared with alprazolam and lorazepam in the treatment of anxious patients: A double-blind study. Aug, 409–412

Alzheimer's Disease
Combination therapy with lecithin and ergoloid mesylates for Alzheimer's disease. May, 249–251
EEG and CT scan in Alzheimer's disease (letter). Apr, 217–218
Haloperidol versus thioridazine in the treatment of behavioral symptoms in senile dementia of the Alzheimer's type: Preliminary findings. June, 310–312
Sleep-disordered breathing in normal and pathologic aging. Oct, 499–503

Amines
Clinical studies on the phenylethylamine hypothesis of affective disorder: Urine and blood phenylacetic acid and phenylalanine dietary supplements. Feb, 66–70
Urinary amine metabolite excretion in a patient with adrenergic hyperactivity state: Reaction to phenelzine withdrawal and combined treatment. Feb, 92–93

Amitriptyline
A comparison of the effects of trazodone and amitriptyline on skills performance by geriatric subjects. May, 252–254
Comparative effects of limbitrol and amitriptyline on sleep efficiency and architecture. Dec, 587–591
The DST as a predictor of acute response to treatment with ECT, chlorimipramine, amitriptyline, and phenelzine. Mar, 139–140
Treating delusional depressives with amitriptyline. May, 243–246

Amnesia
Amnesia as a presenting symptom in subacute bacterial endocarditis. July, 383–384

Amoxapine
Suppression of tardive dyskinesia with amoxapine: Case report. Mar, 148
Withdrawal dyskinesia following amoxapine therapy (letter). June, 329–330

Anesthetic Agents
Atropine and glycopyrrolate as ECT preanesthesia. Apr, 199–200

Anorexia
Anorexia nervosa in a young man with Tourette's syndrome. June, 324–326
Renal disease and dysfunction in two patients with anorexia nervosa. Aug, 433–434

Anticholinergic Agents
Anticholinergic agents for prophylaxis of neuroleptic-induced dystonic reactions: A prospective study. June, 305–309
Neuroleptic dose and the need for prophylactic anticholinergic drugs (letter with reply). Dec, 611
Possibility of hyperpyrexia with antipsychotic and anticholinergic drugs (letter with reply). Nov, 571

Antidepressants: See also specific drugs and Tricyclic Antidepressants
Antidepressant drug therapy for bulimia: Current status. July, 339–345
Antidepressant treatment for posttraumatic stress disorder (PTSD) (letter). May, 275
Are antidepressant trials too short? A case report. Jan, 38–39
Depression: Medical interface with psychiatry and treatment advances. Oct, Suppl, 31–36
Pattern analysis of antidepressant response to fluoxetine. Nov, 560–562
Simultaneous panic and depressive disorder: Response to antidepressant treatment. Jan, 4–7
The dexamethasone suppression test and response to somatic treatment: A review. Jan, 16–21
Therapeutic monitoring of antidepressant drugs: Current methodology and applications. Oct, Suppl, 39–50

Antiparkinsonian Drugs: See also specific drugs
Anticholinergic agents for prophylaxis of neuroleptic-induced dystonic reactions: A prospective study. June, 305–309
Evaluation of the need for prophylactic antiparkinsonian medication in psychotic patients treated with neuroleptics. Mar, 114–116
Use or abuse of antiparkinsonian drugs by psychiatric patients. Mar, 130–132

Antipsychotic Drugs: See also specific drugs
Antipsychotic drugs and the elderly. May, Suppl, 17–22
"Antipsychotic" or "neuroleptic" (letter). July, 392
Possibility of hyperpyrexia with antipsychotic and anticholinergic drugs (letter with reply). Nov, 571

Anxiety
Alprazolam as an adjunct to propranolol in anxious outpatients with stable angina pectoris. Jan, 8–11
Anxiety attacks in a patient with a right temporal lobe meningioma. May, 270–271
Current trends in clinical research on panic attacks, agoraphobia, and related anxiety disorders. June, Suppl, 37–39
Early placebo response in anxious and depressed patients. May, 230–233
Effect of alprazolam and diazepam on anxiety and panic attacks in panic disorder: A controlled study. Sept, 458–460
Introduction. June, Suppl, 3
Low-sedation potential of buspirone compared with alprazolam and lorazepam in the treatment of anxious patients: A double-blind study. Aug, 409–412
Pharmacotherapeutic considerations in anxiety disorders. June, Suppl, 33–36
Reversibility of serotonin irritation syndrome with atmospheric anions. Mar, 141–143
The epidemiology of anxiety and panic disorders: An update. June, Suppl, 11–17

Attention Deficit Disorder
A case of Tourette's syndrome with symptoms of attention deficit disorder treated with desipramine. Sept, 478–479
Tourette's syndrome and attention deficit disorder (letter). June, 330

Baclofen
Baclofen treatment in a patient with tardive dystonia. Sept, 474–475

Journal of Clinical Psychiatry

Subject Index to Volume 47: January 1986 Through December 1986

Addison's Disease
S. Weir Mitchell's early fictional reference to Addison's disease (letter). May, 278

Adolescents
Mania in adolescence. Dec, 596–599
Psychotropic medication in adolescents: A review. Aug, 400–408

Affective Disorders
A hypergraphic syndrome of automatic writing, affective disorder, and temporal lobe epilepsy in two patients. May, 255–257
Affective disorders and associated psychopathology: A family history study. Apr, 162–169
Brain imaging in the search for biological markers in affective disorder. Oct, Suppl, 7–10
Clinical studies on the phenylethylamine hypothesis of affective disorder: Urine and blood phenylacetic acid and phenylalanine dietary supplements. Feb, 66–70
Effect of carbamazepine on body weight in affectively ill patients. June, 313–314
Is postpsychotic depression a primary affective disorder? (letter with reply). Sept, 482
Mixed cognitive-affective disturbances in the elderly: A new classification. July, 354–356
Pathological gambling and major affective disorder: Preliminary findings. Apr, 201–203
Premenstrual tension syndrome in rapid-cycling bipolar affective disorder. Aug, 415–417
Update on neuroreceptor mechanisms and their implication for the pharmacotherapy of affective disorders. Oct, Suppl, 13–18

Agoraphobia
Agoraphobia: Relative and combined effectiveness of therapist-assisted *in vivo* exposure and imipramine. Mar, 117–122
Current trends in clinical research on panic attacks, agoraphobia, and related anxiety disorders. June, Suppl, 37–39
Treatment of panic disorder and agoraphobia with clonazepam. May, 238–242

Alcohol and Alcoholism
Intravenous drug use in alcoholics. Nov, 551–554
Modulation of ethanol intake by serotonin uptake inhibitors. Apr, Suppl, 16–22
Obsessive-compulsive disorder and alcoholism (letter with reply). Mar, 153
Physostigmine in alcohol withdrawal: A new clinical approach (letter). Oct, 530
The effect of alcoholism on membrane lithium transport. July, 350–353

Alprazolam
Alprazolam as an adjunct to propranolol in anxious outpatients with stable angina pectoris. Jan, 8–11
Alprazolam in the treatment of bulimia (letter). Jan, 49
Alprazolam treatment for panic disorders. June, 301–304
Comparative efficacy of alprazolam, imipramine, and placebo administered once a day in treating depressed patients. July, 357–361
Drug treatment of panic disorder: The comparative efficacy of imipramine, alprazolam, and trazodone. Dec, 580–586
Effect of alprazolam and diazepam on anxiety and panic attacks in panic disorder: A controlled study. Sept, 458–460
Low-sedation potential of buspirone compared with alprazolam and lorazepam in the treatment of anxious patients: A double-blind study. Aug, 409–412

Alzheimer's Disease
Combination therapy with lecithin and ergoloid mesylates for Alzheimer's disease. May, 249–251
EEG and CT scan in Alzheimer's disease (letter). Apr, 217–218
Haloperidol versus thioridazine in the treatment of behavioral symptoms in senile dementia of the Alzheimer's type: Preliminary findings. June, 310–312
Sleep-disordered breathing in normal and pathologic aging. Oct, 499–503

Amines
Clinical studies on the phenylethylamine hypothesis of affective disorder: Urine and blood phenylacetic acid and phenylalanine dietary supplements. Feb, 66–70
Urinary amine metabolite excretion in a patient with adrenergic hyperactivity state: Reaction to phenelzine withdrawal and combined treatment. Feb, 92–93

Amitriptyline
A comparison of the effects of trazodone and amitriptyline on skills performance by geriatric subjects. May, 252–254
Comparative effects of limbitrol and amitriptyline on sleep efficiency and architecture. Dec, 587–591
The DST as a predictor of acute response to treatment with ECT, chlorimipramine, amitriptyline, and phenelzine. Mar, 139–140
Treating delusional depressives with amitriptyline. May, 243–246

Amnesia
Amnesia as a presenting symptom in subacute bacterial endocarditis. July, 383–384

Amoxapine
Suppression of tardive dyskinesia with amoxapine: Case report. Mar, 148
Withdrawal dyskinesia following amoxapine therapy (letter). June, 329–330

Anesthetic Agents
Atropine and glycopyrrolate as ECT preanesthesia. Apr, 199–200

Anorexia
Anorexia nervosa in a young man with Tourette's syndrome. June, 324–326
Renal disease and dysfunction in two patients with anorexia nervosa. Aug, 433–434

Anticholinergic Agents
Anticholinergic agents for prophylaxis of neuroleptic-induced dystonic reactions: A prospective study. June, 305–309
Neuroleptic dose and the need for prophylactic anticholinergic drugs (letter with reply). Dec, 611
Possibility of hyperpyrexia with antipsychotic and anticholinergic drugs (letter with reply). Nov, 571

Antidepressants: See also specific drugs and Tricyclic Antidepressants
Antidepressant drug therapy for bulimia: Current status. July, 339–345
Antidepressant treatment for posttraumatic stress disorder (PTSD) (letter). May, 275
Are antidepressant trials too short? A case report. Jan, 38–39
Depression: Medical interface with psychiatry and treatment advances. Oct, Suppl, 31–36
Pattern analysis of antidepressant response to fluoxetine. Nov, 560–562
Simultaneous panic and depressive disorder: Response to antidepressant treatment. Jan, 4–7
The dexamethasone suppression test and response to somatic treatment: A review. Jan, 16–21
Therapeutic monitoring of antidepressant drugs: Current methodology and applications. Oct, Suppl, 39–50

Antiparkinsonian Drugs: See also specific drugs
Anticholinergic agents for prophylaxis of neuroleptic-induced dystonic reactions: A prospective study. June, 305–309
Evaluation of the need for prophylactic antiparkinsonian medication in psychotic patients treated with neuroleptics. Mar, 114–116
Use or abuse of antiparkinsonian drugs by psychiatric patients. Mar, 130–132

Antipsychotic Drugs: See also specific drugs
Antipsychotic drugs and the elderly. May, Suppl, 17–22
"Antipsychotic" or "neuroleptic" (letter). July, 392
Possibility of hyperpyrexia with antipsychotic and anticholinergic drugs (letter with reply). Nov, 571

Anxiety
Alprazolam as an adjunct to propranolol in anxious outpatients with stable angina pectoris. Jan, 8–11
Anxiety attacks in a patient with a right temporal lobe meningioma. May, 270–271
Current trends in clinical research on panic attacks, agoraphobia, and related anxiety disorders. June, Suppl, 37–39
Early placebo response in anxious and depressed patients. May, 230–233
Effect of alprazolam and diazepam on anxiety and panic attacks in panic disorder: A controlled study. Sept, 458–460
Introduction. June, Suppl, 3
Low-sedation potential of buspirone compared with alprazolam and lorazepam in the treatment of anxious patients: A double-blind study. Aug, 409–412
Pharmacotherapeutic considerations in anxiety disorders. June, Suppl, 33–36
Reversibility of serotonin irritation syndrome with atmospheric anions. Mar, 141–143
The epidemiology of anxiety and panic disorders: An update. June, Suppl, 11–17

Attention Deficit Disorder
A case of Tourette's syndrome with symptoms of attention deficit disorder treated with desipramine. Sept, 478–479
Tourette's syndrome and attention deficit disorder (letter). June, 330

Baclofen
Baclofen treatment in a patient with tardive dystonia. Sept, 474–475

Behavioral Disturbances
Therapeutic effects of pindolol on behavioral disturbances associated with organic brain disease: A double-blind study. Aug, 423–426

Benzodiazepines: See also specific drugs
Are benzodiazepines anticholinergic? (letter with reply). July, 393

Bethanechol Chloride
Bethanechol chloride can reverse erectile and ejaculatory dysfunction induced by tricyclic antidepressants and mazindol: Case report. Apr, 210–211

Bioavailability
Bioavailability of psychotropic drugs: Historical perspective and pharmacokinetic overview. Sept, Suppl, 6–15
Clinical relevance of the bioavailability/bioequivalence controversy. Sept, Suppl, 3–5
Determination of bioequivalence of psychotropic drugs and concerns involving product interchange. Sept, Suppl, 28–32
The significance of pharmacodynamic measurements in the assessment of bioavailability and bioequivalence of psychotropic drugs using CEEG and dynamic brain mapping. Sept, Suppl, 20–27

Biologic Markers
Brain imaging in the search for biological markers in affective disorder. Oct, Suppl, 7–10
Drug intake and the dexamethasone suppression test. Mar, 144–146
Physical complaints correlate better with depression than do dexamethasone suppression test results. Apr, 179–181

Bipolar Disorder
"On-Off" phenomena and manic-depressive mood shifts: Case reports. Feb, 93–94
Appearance of mania in drug-resistant bipolar depressed patients after treatment with L-triiodothyronine. Oct, 521–522
Mania induced by tricyclic-MAOI combination therapy in bipolar treatment-resistant disorder: Case reports. Jan, 40–41
Mixed bipolar disorder responsive to lithium and clonazepam (letter). Jan, 49–50
Premenstrual tension syndrome in rapid-cycling bipolar affective disorder. Aug, 415–417

Blood Abnormalities
Elevated blood neutrophil concentration in mania. Feb, 63–65
Elevated blood neutrophil concentration in mania (letter with reply). June, 331
Psychogenic purpura, idiopathic thrombocytopenic purpura, and platelet dysfunction in the same patient. July, 386–387

Blood Levels
Drug holidays and serum haloperidol levels in schizophrenic patients. July, 373–374
Mesoridazine and thioridazine: Clinical effects and blood levels in refractory schizophrenics. July, 375–379
Psychotropic blood levels: A guide to clinical response. Sept, Suppl, 16–19
Therapeutic monitoring of antidepressant drugs: Current methodology and applications. Oct, Suppl, 39–50
Tricyclic-resistant depression (letter with reply). July, 393
Utility of neuroleptic blood levels in the treatment of acute psychosis. Dec, 600–603

Borderline Personality Disorder
Epidemiology of borderline personality disorder (letter with reply). Dec, 611–612
The demographic profile of borderline personality disorder. Apr, 196–198

Brain Mapping
Koro: Computed tomography and brain electrical activity mapping in two patients. Aug, 430–432
The significance of pharmacodynamic measurements in the assessment of bioavailability and bioequivalence of psychotropic drugs using CEEG and dynamic brain mapping. Sept, Suppl, 20–27

Brain
Brain atrophy and interhemispheric fissure enlargement in Cotard's syndrome. Oct, 518–520

Bulimia
Alprazolam in the treatment of bulimia (letter). Jan, 49
Antidepressant drug therapy for bulimia: Current status. July, 339–345
Bulimia precipitated by pregnancy (letter). May, 275–276
Non-bulimia: Food regurgitation in a patient with self-diagnosed bulimia. June, 317–318
The dexamethasone suppression test in bulimia before and after successful treatment with desipramine. Oct, 515–517

Buspirone
Low-sedation potential of buspirone compared with alprazolam and lorazepam in the treatment of anxious patients: A double-blind study. Aug, 409–412

Calcium Channel Blockers
Verapamil treatment of acute mania. Mar, 136–138

Capgras' Syndrome
Cotard's syndrome in a patient with coexistent Capgras' syndrome, syndrome of subjective doubles, and palinopsia. Dec, 605–606

Captopril
Captopril in the treatment of psychogenic polydipsia (letter). Feb, 99

Carbamazepine
A case of erythromycin-induced carbamazepine toxicity. Mar, 147
Carbamazepine and ECT: A paradoxical combination (letter). May, 276–277
Effect of carbamazepine on body weight in affectively ill patients. June, 313–314
The comparative efficacy and safety of carbamazepine versus lithium: A randomized, double-blind 3-year trial in 83 patients. Oct, 490–494

Cardiac Disease
Alprazolam as an adjunct to propranolol in anxious outpatients with stable angina pectoris. Jan, 8–11

Cardiac Side Effects
Monoamine oxidase inhibitors and tricyclic antidepressants: Comparison of their cardiovascular effects. May, 225–229

Catatonia
Myelin basic protein antibodies in catatonic schizophrenia. Jan, 26–28

Central Nervous System Studies
Can blood immunocytes be used to study neuropsychiatric disorders? Dec, 592–595

Cerebral Dysfunction
Cotard's syndrome in a patient with coexistent Capgras' syndrome, syndrome of subjective doubles, and palinopsia. Dec, 605–606

Cerebral Spinal Fluid
Phencyclidine in CSF and serum: A case of attempted filicide by a mother without a history of substance abuse. Aug, 428–429

CHAMPUS
Reflections of a CHAMPUS-APA peer reviewer. Feb, 71–74

Character Disorder
Axis II character disorders in PTSD (letter with reply). Apr, 217

Child Psychiatry
Prospective study of intake procedures in a child psychiatry clinic. Mar, 111–113

Children
Methylphenidate-induced mania in a prepubertal child. Nov, 566–567

Chlorimipramine
The DST as a predictor of acute response to treatment with ECT, chlorimipramine, amitriptyline, and phenelzine. Mar, 139–140

Chlorpromazine
A case of lithium-chlorpromazine interaction. Feb, 90–91

Cigarette Smoking
The multiple dangers of smoking (letter). Apr, 218

Cimetidine
Cimetidine and mental status changes (letter). Feb, 99–100

Clonazepam
Clonazepam blockade of spontaneous and CO_2 inhalation-provoked panic in a patient with panic disorder. Sept, 475–476
Clonazepam in the treatment of patients with recurrent panic attacks. Feb, 83–85
Clonazepam treatment of organic brain syndromes in three elderly patients. Oct, 525–526
Mixed bipolar disorder responsive to lithium and clonazepam (letter). Jan, 49–50
Treatment of panic disorder and agoraphobia with clonazepam. May, 238–242

Clonidine
Clonidine and verapamil in the treatment of mania (letter with reply). Nov, 570

CME Tests
CME Tests. May, Suppl, 34–36

Cocaine
Sexual dysfunction secondary to cocaine abuse in two patients. July, 384–385

Cognition, Tests of
Tests of cognition and their relationship to psychiatric diagnosis and demographic variables. Oct, 495–498

Cognitive Dysfunction
Mixed cognitive-affective disturbances in the elderly: A new classification. July, 354–356
Opiate antagonism fails to reverse post-ECT cognitive deficits. Nov, 555–556

Combination Therapy
Combination therapy with lecithin and ergoloid mesylates for Alzheimer's disease. May, 249–251

Computed Tomography
EEG and CT scan in Alzheimer's disease (letter). Apr, 217–218
Koro: Computed tomography and brain electrical activity mapping in two patients. Aug, 430–432

Continuation Treatment: See also Maintenance Treatment
Phenelzine for chronic depression: A study of continuation treatment. July, 346–349

Corrections
Extein I, Gold MS: Psychiatric applications of thyroid tests (47, 1 Suppl:13). Feb, 65
Silver H: Physical complaints correlate better with depression than do dexamethasone suppression test results (47:179). Sept, 483
Weiler MA, Jobe TH, Nasr SJ, Pandey G, Altman E: 4 p.m. baseline cortisol level as a predictor of DST results in depression (47:60). Apr, 209
Zisook S, Janowsky DS, Overall JE, Risch SC: The dexamethasone suppression test and unipolar/bipolar distinctions (46:461). Feb, 70

Cortisol Suppression Index
Low utility of the CSI in depressed elderly patients with medical disturbances (letter). May, 275

Cortisol
4 p.m. baseline cortisol level as a predictor of DST results in depression. Feb, 60–62

Cotard's Syndrome
Brain atrophy and interhemispheric fissure enlargement in Cotard's syndrome. Oct, 518–520
Cotard's syndrome in a patient with coexistent Capgras' syndrome, syndrome of subjective doubles, and palinopsia. Dec, 605–606

Danazol
Danazol and the rapid-cycling patient (letter). Mar, 153–154

Dementia
Antipsychotic drugs and the elderly. May, Suppl, 17–22
Mixed cognitive-affective disturbances in the elderly: A new classification. July, 354–356
Progressive dementia associated with thyroid disease (letter). Feb, 100
Psychopathology in paraneoplastic encephalopathy: An electroclinical observation. May, 267–268
Revised ischemic score for diagnosing multi-infarct dementia (letter with reply). Aug, 437
Trazodone in dementia (letter). Sept, 482

Depression
4 p.m. baseline cortisol level as a predictor of DST results in depression. Feb, 60–62
Comparative efficacy of alprazolam, imipramine, and placebo administered once a day in treating depressed patients. July, 357–361
Depression and substance abuse in handicapped young men. May, 234–237
Depression correlated wtih cellular immunity in systemic immunodeficient Epstein-Barr virus syndrome (SIDES). Mar, 133–135
Depression: Medical interface with psychiatry and treatment advances. Oct, Suppl, 31–36
ECT in primary and secondary depression. June, 298–300
Early placebo response in anxious and depressed patients. May, 230–233
Elderly depressed females as a possible subgroup of patients responsive to methylphenidate. Sept, 467–469
Epstein-Barr virus infection and depression (letter with reply). Oct, 529
Hyperthyroidism in a patient with agitated depression: Resolution after electroconvulsive therapy. June, 322–323
Low utility of the CSI in depressed elderly patients with medical disturbances (letter). May, 275
Mixed cognitive-affective disturbances in the elderly: A new classification. July, 354–356
Phenelzine for chronic depression: A study of continuation treatment. July, 346–349
Physical complaints correlate better with depression than do dexamethasone suppression test results. Apr, 179–181
Plasma levels of cortisol, corticotropin, and β-endorphin in patients with major depression. Aug, 413–414
Response of energy and suicidal ideation to ECT. Jan, 31–32
Simultaneous panic and depressive disorder: Response to antidepressant treatment. Jan, 4–7
The stimulant challenge test in depression. Nov, 538–543
Therapeutic effects of serotonin uptake inhibitors in depression. Apr, Suppl, 23–35
Tricyclic-resistant depression (letter with reply). July, 393

Depression, Atypical
Atypical depression and seasonal energy syndrome (letter). Feb, 98
Tranylcypromine: Patterns and predictors of response. July, 380–382

Depression, Delusional
ECT in delusionally depressed patients (letter). Apr, 219
ECT response in psychotic versus nonpsychotic unipolar depressives. Mar, 123–125
Treating delusional depressives with amitriptyline. May, 243–246

Depression, Postpsychotic
Is postpsychotic depression a primary affective disorder? (letter with reply). Sept, 482
Psychostimulants and schizophrenic relapse (letter). Jan, 48
Stability of the postpsychotic depression syndrome. Feb, 86–88

Depression, Poststroke
Electroconvulsive therapy for poststroke depression. May, 258–260

Depression, Secondary
Psychostimulant treatment of depressive disorders secondary to medical illness. Jan, 12–15

Depression, Unipolar
ECT response in psychotic versus nonpsychotic unipolar depressives. Mar, 123–125

Depressive Symptoms
Depressive symptoms in acute schizophrenic inpatients (letter with reply). June, 329
Depressive symptoms in propranolol users. Sept, 453–457

Desipramine
A case of Tourette's syndrome with symptoms of attention deficit disorder treated with desipramine. Sept, 478–479
The dexamethasone suppression test in bulimia before and after successful treatment with desipramine. Oct, 515–517

Dexamethasone Suppression Test
4 p.m. baseline cortisol level as a predictor of DST results in depression. Feb, 60–62
Clinical and DST response to bilateral sinusoidal but not to unilateral brief-pulse ECT. Nov, 557–559
DST has no predictive ability for acute response to ECT (letter with reply). Dec, 612
Drug intake and the dexamethasone suppression test. Mar, 144–146
Informed use of the dexamethasone suppression test. Jan, Suppl, 10–12
Physical complaints correlate better with depression than do dexamethasone suppression test results. Apr, 179–181
The DST as a predictor of acute response to treatment with ECT, chlorimipramine, amitriptyline, and phenelzine. Mar, 139–140
The dexamethasone suppression test in bulimia before and after successful treatment with desipramine. Oct, 515–517
The dexamethasone suppression test and response to somatic treatment: A review. Jan, 16–21

Dextramphetamine
Psychostimulant treatment of depressive disorders secondary to medical illness. Jan, 12–15

Diabetes Mellitus
Eating disorders in patients with insulin-dependent diabetes mellitus. Nov, 547–550

Diagnosis/Classification
Application of Research Diagnostic Criteria and International Classification of Diseases to case vignettes. Feb, 78–80
DSM-III diagnoses in social security disability applicants referred for psychiatric evaluation. Feb, 81–82
Diagnostic considerations in panic disorders. June, Suppl, 4–10
King Saul as a patient (letter). Nov, 572
MMPI correlates of obsessive-compulsive disorder. July, 371–372
Mixed cognitive-affective disturbances in the elderly: A new classification. July, 354–356
Pathophysiology of panic: A review of pharmacologic provocative tests and naturalistic monitoring data. June, Suppl, 18–26
Tests of cognition and their relationship to psychiatric diagnosis and demographic variables. Oct, 495–498
The demographic profile of borderline personality disorder. Apr, 196–198

Diagnostic Techniques
Pathophysiology of panic: A review of pharmacologic provocative tests and naturalistic monitoring data. June, Suppl, 18–26

Diazepam
Effect of alprazolam and diazepam on anxiety and panic attacks in panic disorder: A controlled study. Sept, 458–460

Dietary Supplements
Clinical studies on the phenylethylamine hypothesis of affective disorder: Urine and blood phenylacetic acid and phenylalanine dietary supplements. Feb, 66–70

Differential Diagnosis
Amnesia as a presenting symptom in subacute bacterial endocarditis. July, 383–384
MMPI correlates of obsessive-compulsive disorder. July, 371–372
Phencyclidine in CSF and serum: A case of attempted filicide by a mother without a history of substance abuse. Aug, 428–429
Physical complaints correlate better with depression than do dexamethasone suppression test results. Apr, 179–181
Revised ischemic score for diagnosing multi-infarct dementia (letter with reply). Aug, 437
Tests of cognition and their relationship to psychiatric diagnosis and demographic variables. Oct, 495–498

Disability
DSM-III diagnoses in social security disability applicants referred for psychiatric evaluation. Feb, 81–82

Dosage Studies/Prediction
Depot neuroleptics: A comparative review of standard, intermediate, and low-dose regimens. May, Suppl, 30–33
Early, targeted pharmacotherapeutic intervention in schizophrenia. May, Suppl, 23–29
Kinetics and dynamics of single doses of oxazepam in the elderly: Implications of absorption rate. Oct, 511–514
Low-dose treatment strategies. May, Suppl, 12–16
Neuroleptic dose and the need for prophylactic anticholinergic drugs (letter with reply). Dec, 611
Prediction of lithium dose: A mathematical alternative to the test-dose method. Apr, 175–178
The future of neuroleptic psychopharmacology. May, Suppl, 3–11
Tranylcypromine: Patterns and predictors of response. July, 380–382

Dothiepin
Dothiepin hydrochloride: Treatment efficacy and safety. Oct, 504–507

Droperidol
Coma following ECT and intravenous droperidol: Case report. Feb, 94–95

Drug Abuse
Depression and substance abuse in handicapped young men. May, 234–237
Intravenous drug use in alcoholics. Nov, 551–554
Role of the laboratory in the evaluation of suspected drug abuse. Jan, Suppl, 17–23
Sexual dysfunction secondary to cocaine abuse in two patients. July, 384–385
Use or abuse of antiparkinsonian drugs by psychiatric patients. Mar, 130–132

Drug Interactions
A case of erythromycin-induced carbamazepine toxicity. Mar, 147
A case of lithium-chlorpromazine interaction. Feb, 90–91
Drug intake and the dexamethasone suppression test. Mar, 144–146
Failure of sulindac to increase serum lithium levels. Jan, 33–34

Drug Withdrawal Phenomena
Persistent abdominal complaints after discontinuation of phenothiazines (letter). Jan, 48–49

DSM-III
Assessment of DSM-III personality disorders: The importance of interviewing an informant. May, 261–263
DSM-III diagnoses in social security disability applicants referred for psychiatric evaluation. Feb, 81–82

Dysgraphia
A hypergraphic syndrome of automatic writing, affective disorder, and temporal lobe epilepsy in two patients. May, 255–257

Dystonia
Anticholinergic agents for prophylaxis of neuroleptic-induced dystonic reactions: A prospective study. June, 305–309
Baclofen treatment in a patient with tardive dystonia. Sept, 474–475
Relationship between dystonia and serum calcium levels. Aug, 418–419

Eating Disorders
Eating disorders in patients with insulin-dependent diabetes mellitus. Nov, 547–550

Efficacy Studies
Clinical relevance of the bioavailability/bioequivalence controversy. Sept, Suppl, 3–5
Comparative effects of limbitrol and amitriptyline on sleep efficiency and architecture. Dec, 587–591
Comparative efficacy of alprazolam, imipramine, and placebo administered once a day in treating depressed patients. July, 357–361
Comparative efficacy of estazolam, flurazepam, and placebo in outpatients with insomnia. July, 362–365
Dothiepin hydrochloride: Treatment efficacy and safety. Oct, 504–507

Drug treatment of panic disorder: The comparative efficacy of imipramine, alprazolam, and trazodone. Dec, 580–586
The comparative efficacy and safety of carbamazepine versus lithium: A randomized, double-blind 3-year trial in 83 patients. Oct, 490–494
Electroconvulsive Therapy
Atropine and glycopyrrolate as ECT preanesthesia. Apr, 199–200
Carbamazepine and ECT: A paradoxical combination (letter). May, 276–277
Clinical and DST response to bilateral sinusoidal but not to unilateral brief-pulse ECT. Nov, 557–559
Coma following ECT and intravenous droperidol: Case report. Feb, 94–95
DST has no predictive ability for acute response to ECT (letter with reply). Dec, 612
ECT during and after the neuroleptic malignant syndrome: Case report. Jan, 42–43
ECT in delusionally depressed patients (letter). Apr, 219
ECT in primary and secondary depression. June, 298–300
ECT response in psychotic versus nonpsychotic unipolar depressives. Mar, 123–125
Electroconvulsive therapy for poststroke depression. May, 258–260
Enhancement of ECT benefit by yohimbine. Oct, 508–510
Hyperthyroidism in a patient with agitated depression: Resolution after electroconvulsive therapy. June, 322–323
Improvement of phencyclidine-associated psychosis with ECT. Sept, 477–478
Mania associated with electroconvulsive therapy. July, 366–367
Opiate antagonism fails to reverse post-ECT cognitive deficits. Nov, 555–556
Response of depressed patients to sequential unilateral nondominant brief-pulse and bilateral sinusoidal ECT. Apr, 182–186
Response of energy and suicidal ideation to ECT. Jan, 31–32
The DST as a predictor of acute response to treatment with ECT, chlorimipramine, amitriptyline, and phenelzine. Mar, 139–140
The dexamethasone suppression test and response to somatic treatment: A review. Jan, 16–21
Electroencephalograph
EEG and CT scan in Alzheimer's disease (letter). Apr, 217–218
Encephalopathy
Psychopathology in paraneoplastic encephalopathy: An electroclinical observation. May, 267–268
Epidemiology
Epidemiology of borderline personality disorder (letter with reply). Dec, 611–612
Panic disorder: Epidemiology, diagnosis, and treatment in primary care. Oct, Suppl, 21–27
The epidemiology of anxiety and panic disorders: An update. June, Suppl, 11–17
Epilepsy
A hypergraphic syndrome of automatic writing, affective disorder, and temporal lobe epilepsy in two patients. May, 255–257
Epstein-Barr Virus
Depression correlated with cellular immunity in systemic immunodeficient Epstein-Barr virus syndrome (SIDES). Mar, 133–135
Epstein-Barr virus infection and depression (letter with reply). Oct, 529
Treatment of chronic Epstein-Barr virus disease with H_2 blockers (letter). Nov, 572
Estazolam
Comparative efficacy of estazolam, flurazepam, and placebo in outpatients with insomnia. July, 362–365
Extrapyramidal Symptoms
Tremor and tardive dyskinesia. Sept, 461–464
Use of hypnosis in EPS-associated anxiety (letter). Feb, 98
Use or abuse of antiparkinsonian drugs by psychiatric patients. Mar, 130–132
Withdrawal dyskinesia following amoxapine therapy (letter). June, 329–330
Family Studies
Affective disorders and associated psychopathology: A family history study. Apr, 162–169
Pathological gambling and major affective disorder: Preliminary findings. Apr, 201–203
Fluoxetine
Pattern analysis of antidepressant response to fluoxetine. Nov, 560–562
Fluphenazine
Low-dose treatment strategies. May, Suppl, 12–16
Relapse in chronic schizophrenics treated with fluphenazine decanoate is associated with low serum neuroleptic levels. May, 247–248
Flurazepam
Comparative efficacy of estazolam, flurazepam, and placebo in outpatients with insomnia. July, 362–365
Folic Acid
Is folate deficiency a side effect of lithium therapy? (letter). May, 276
Serum folate levels in U.S. psychiatric inpatients (letter). Feb, 98–99
Forensic Psychiatry
Disagreement between court and psychiatrist on competency to stand trial. Jan, 29–30
Recidivism of the criminally insane in France: A 22-year follow-up. Sept, 465–466
Gambling
Pathological gambling and major affective disorder: Preliminary findings. Apr, 201–203
Generalized Anxiety Disorder
Effective short-term treatment of generalized anxiety disorder with trifluoperazine. Apr, 170–174
Generic Drugs
Behavioral changes following generic thioridazine (letter). May, 277–278
Geriatric Patients
A comparison of the effects of trazodone and amitriptyline on skills performance by geriatric subjects. May, 252–254
Antipsychotic drugs and the elderly. May, Suppl, 17–22
Clonazepam treatment of organic brain syndromes in three elderly patients. Oct, 525–526
Elderly depressed females as a possible subgroup of patients responsive to methylphenidate. Sept, 467–469
Kinetics and dynamics of single doses of oxazepam in the elderly: Implications of absorption rate. Oct, 511–514
Low utility of the CSI in depressed elderly patients with medical disturbances (letter). May, 275
Mixed cognitive-affective disturbances in the elderly: A new classification. July, 354–356
Sleep-disordered breathing in normal and pathologic aging. Oct, 499–503
Haloperidol
A comparison of parenteral loxapine and haloperidol in hostile and aggressive acutely schizophrenic patients. Mar, 126–129
Drug holidays and serum haloperidol levels in schizophrenic patients. July, 373–374
Haloperidol versus thioridazine in the treatment of behavioral symptoms in senile dementia of the Alzheimer's type: Preliminary findings. June, 310–312
Low-dose treatment strategies. May, Suppl, 12–16
Monosymptomatic hypochondriacal psychosis manifesting as delusions of infestation: Case studies of treatment with haloperidol. Apr, 188–190
Handicap, Physical
Depression and substance abuse in handicapped young men. May, 234–237
Hyperpyrexia
Possibility of hyperpyrexia with antipsychotic and anticholinergic drugs (letter with reply). Nov, 571
Hypertension
Mysterious MAOI hypertensive episodes. Nov, 563–565
The effect of alcoholism on membrane lithium transport. July, 350–353
Hyperthyroidism
Hyperthyroidism in a patient with agitated depression: Resolution after electroconvulsive therapy. June, 322–323
Lithium treatment of hyperthyroidism and mania. May, 264–266
Hypnosis
Use of hypnosis in EPS-associated anxiety (letter). Feb, 98
Imipramine
Agoraphobia: Relative and combined effectiveness of therapist-assisted *in vivo* exposure and imipramine. Mar, 117–122
Comparative efficacy of alprazolam, imipramine, and placebo administered once a day in treating depressed patients. July, 357–361
Drug treatment of panic disorder: The comparative efficacy of imipramine, alprazolam, and trazodone. Dec, 580–586
Immunologic Studies
Can blood immunocytes be used to study neuropsychiatric disorders? Dec, 592–595
Myelin basic protein antibodies in catatonic schizophrenia. Jan, 26–28
Insomnia
Comparative efficacy of estazolam, flurazepam, and placebo in outpatients with insomnia. July, 362–365
International Classification of Diseases
Application of Research Diagnostic Criteria and International Classification of Diseases to case vignettes. Feb, 78–80
Irritable Bowel Syndrome
Can panic disorder present as irritable bowel syndrome? Sept, 470–473
Joseph Disease
Exacerbation of tardive dyskinesia by Joseph disease. June, 315–316
Koro
Koro: Computed tomography and brain electrical activity mapping in two patients. Aug, 430–432
L-Phenylalanine
Clinical studies on the phenylethylamine hypothesis of affective disorder: Urine and blood phenylacetic acid and phenylalanine dietary supplements. Feb, 66–70
L-Triiodothronine
Appearance of mania in drug-resistant bipolar depressed patients after treatment with L-triiodothyronine, Oct, 521–522
Laboratory Analyses
Psychiatric applications of thyroid tests. Jan, Suppl, 13–16
Role of the laboratory in the evaluation of suspected drug abuse, Jan, Suppl, 17–23
Testing for physical illness in psychiatric patients. Jan, Suppl, 3–9
Lecithin
Combination therapy with lecithin and ergoloid mesylates for Alzheimer's disease. May, 249–251
Limbitrol
Comparative effects of limbitrol and amitriptyline on sleep efficiency and architecture. Dec, 587–591
Lithium
A case of lithium-chlorpromazine interaction. Feb, 90–91
Failure of sulindac to increase serum lithium levels. Jan, 33–34
Is folate deficiency a side effect of lithium therapy? (letter). May, 276
Lithium associated with psoriasis (letter). June, 330
Lithium treatment of hyperthyroidism and mania. May, 264–266
Mixed bipolar disorder responsive to lithium and clonazepam (letter). Jan, 49–50
Prediction of lithium dose: A mathematical alternative to the test-dose method. Apr, 175–178
Report of a patient with lithium-related alopecia and psoriasis. Apr, 212
Successful treatment of lithium-induced acne (letter). Jan, 48
The comparative efficacy and safety of carbamazepine versus lithium: A randomized, double-blind 3-year trial in 83 patients. Oct, 490–494

The effect of alcoholism on membrane lithium transport. July, 350–353

Lorazepam

Low-sedation potential of buspirone compared with alprazolam and lorazepam in the treatment of anxious patients: A double-blind study. Aug, 409–412

Loxapine

A comparison of parenteral loxapine and haloperidol in hostile and aggressive acutely schizophrenic patients. Mar, 126–129

Rapid tranquilization: A comparison of thiothixene with loxapine. June, 294–297

Maintenance Treatment: See also Continuation Treatment

A comparison of parenteral loxapine and haloperidol in hostile and aggressive acutely schizophrenic patients. Mar, 126–129

Depot neuroleptics: A comparative review of standard, intermediate, and low-dose regimens. May, Suppl, 30–33

Phenelzine for chronic depression: A study of continuation treatment. July, 346–349

Mania

Appearance of mania in drug-resistant bipolar depressed patients after treatment with L-triiodothyronine. Oct, 521–522

Clonidine and verapamil in the treatment of mania (letter with reply). Nov, 570

Elevated blood neutrophil concentration in mania. Feb, 63–65

Elevated blood neutrophil concentration in mania (letter with reply). June, 331

Lithium treatment of hyperthyroidism and mania. May, 264–266

Mania associated with electroconvulsive therapy. July, 366–367

Mania in adolescence. Dec, 596–599

Mania induced by tricyclic-MAOI combination therapy in bipolar treatment-resistant disorder: Case reports. Jan, 40–41

Methylphenidate-induced mania in a prepubertal child. Nov, 566–567

Verapamil treatment of acute mania. Mar, 136–138

MAO Inhibitors

Mania induced by tricyclic-MAOI combination therapy in bipolar treatment-resistant disorder: Case reports. Jan, 40–41

Monoamine oxidase inhibitor-induced speech blockage. Dec, 604

Monoamine oxidase inhibitors and tricyclic antidepressants: Comparison of their cardiovascular effects. May, 225–229

Mysterious MAOI hypertensive episodes. Nov, 563–565

Overdose with moclobemide (letter). Aug, 438

Phenelzine for chronic depression: A study of continuation treatment. July, 346–349

Mazindol

Bethanechol chloride can reverse erectile and ejaculatory dysfunction induced by tricyclic antidepressants and mazindol: Case report. Apr, 210–211

Medical Illness

Low utility of the CSI in depressed elderly patients with medical disturbances (letter). May, 275

Psychostimulant treatment of depressive disorders secondary to medical illness. Jan, 12–15

Testing for physical illness in psychiatric patients. Jan, Suppl, 3–9

Melancholia

Phenelzine treatment of melancholia. Aug, 420–422

Methylphenidate

Elderly depressed females as a possible subgroup of patients responsive to methylphenidate. Sept, 467–469

Methylphenidate-induced mania in a prepubertal child. Nov, 566–567

Psychostimulant treatment of depressive disorders secondary to medical illness. Jan, 12–15

Tics with combined thioridazine-methylphenidate therapy: Case report. Jan, 44–45

Metoclopramide

Organic affective syndrome associated wtih metoclopramide: Case report. Apr, 208–209

Moclobemide

Overdose with moclobemide (letter). Aug, 438

Mesoridazine

Mesoridazine and thioridazine: Clinical effects and blood levels in refractory schizophrenics. July, 375–379

Molindone

A case of massive rhabdomyolysis following molindone administration. Dec, 607–608

Movement Disorders

A case of progressive hemichorea responsive to high-dose reserpine. Mar, 149–150

Multiple Personality Disorder

Psychosexual disturbances in multiple personality: Characteristics, etiology, and treatment. Mar, 106–110

The clinical phenomenology of multiple personality disorder: Review of 100 recent cases. June, 285–293

Naloxone

Opiate antagonism fails to reverse post-ECT cognitive deficits. Nov, 555–556

Neuroleptic Malignant Syndrome

Central dopaminergic and noradrenergic receptor blockade in a patient with neuroleptic malignant syndrome. June, 320–321

ECT during and after the neuroleptic malignant syndrome: Case report. Jan, 42–43

Early diagnosis of neuroleptic malignant syndrome (letter). Mar, 154

Neuroleptic malignant syndrome (letter). Sept, 483

Neuroleptics

Anticholinergic agents for prophylaxis of neuroleptic-induced dystonic reactions: A prospective study. June, 305–309

"Antipsychotic" or "neuroleptic" (letter). July, 392

Depot neuroleptics: A comparative review of standard, intermediate, and low-dose regimens. May, Suppl, 30–33

Early, targeted pharmacotherapeutic intervention in schizophrenia. May, Suppl, 23–29

Evaluation of the need for prophylactic antiparkinsonian medication in psychotic patients treated with neuroleptics. Mar, 114–116

Low-dose treatment strategies. May, Suppl, 12–16

Mesoridazine and thioridazine: Clinical effects and blood levels in refractory schizophrenics. July, 375–379

Neuroleptic dose and the need for prophylactic anticholinergic drugs (letter with reply). Dec, 611

Neuroleptic drug-induced coagulopathy: Mechanism of reaction and duration of effect. Jan, 35–37

Persistent abdominal complaints after discontinuation of phenothiazines (letter). Jan, 48–49

Relapse in chronic schizophrenics treated with fluphenazine decanoate is associated with low serum neuroleptic levels. May, 247–248

The future of neuroleptic psychopharmacology. May, Suppl, 3–11

Use or abuse of antiparkinsonian drugs by psychiatric patients. Mar, 130–132

Utility of neuroleptic blood levels in the treatment of acute psychosis. Dec, 600–603

Neurologic Disorders

Anxiety attacks in a patient with a right temporal lobe meningioma. May, 270–271

Can blood immunocytes be used to study neuropsychiatric disorders? Dec, 592–596

Neurotransmitters

Pharmacologic probes of neurotransmitter systems in tardive dyskinesia: Implications for clinical management. Feb, 56–59

Use of serotonergic agents in the clinical assessment of central serotonin function. Apr, Suppl, 9–15

Obsessive-Compulsive Disorder

MMPI correlates of obsessive-compulsive disorder. July, 371–372

Obsessive-compulsive disorder and alcoholism (letter with reply). Mar, 153

Organic Brain Disorders

Clonazepam treatment of organic brain syndromes in three elderly patients. Oct, 525–526

Improvement in organically disturbed behavior with trazodone treatment. Apr, 191–193

Late-life paraphrenia: An organic delusional syndrome. Apr, 204–207

Organic affective syndrome associated with metoclopramide: Case report. Apr, 208–209

Therapeutic effects of pindolol on behavioral disturbances associated with organic brain disease: A double-blind study. Aug, 423–426

Overdose

Overdose with moclobemide (letter). Aug, 438

Trazodone overdose: Four years of experience from voluntary reports. Nov, 544–546

Triazolam overdose (letter). Jan, 50

Oxazepam

Kinetics and dynamics of single doses of oxazepam in the elderly: Implications of absorption rate. Oct, 511–514

Panic Attacks: See also Anxiety

Clonazepam blockade of spontaneous and CO_2 inhalation-provoked panic in a patient with panic disorder. Sept, 475–476

Clonazepam in the treatment of patients with recurrent panic attacks. Feb, 83–85

Current trends in clinical research on panic attacks, agoraphobia, and related anxiety disorders. June, Suppl, 37–39

Effect of alprazolam and diazepam on anxiety and panic attacks in panic disorder: A controlled study. Sept, 458–460

Panic attacks and psychomotor seizures following right temple lobectomy (letter). Apr, 219

Panic Disorder

Alprazolam treatment for panic disorders. June, 301–304

Can panic disorder present as irritable bowel syndrome? Sept, 470–473

Clonazepam blockade of spontaneous and CO_2 inhalation-provoked panic in a patient with panic disorder. Sept, 475–476

Diagnostic considerations in panic disorders. June, Suppl, 4–10

Drug treatment of panic disorder: The comparative efficacy of imipramine, alprazolam, and trazodone. Dec, 580–586

Effect of alprazolam and diazepam on anxiety and panic attacks in panic disorder: A controlled study. Sept, 458–460

Introduction. June, Suppl, 3

Nonsteroidal anti-inflammatory drugs and panic disorder (letter). May, 277

Panic disorder: Epidemiology, diagnosis, and treatment in primary care. Oct, Suppl, 21–27

Pathophysiology of panic: A review of pharmacologic provocative tests and naturalistic monitoring data. June, Suppl, 18–26

Pharmacotherapy of the panic disorders. June, Suppl, 27–32

Simultaneous panic and depressive disorder: Response to antidepressant treatment. Jan, 4–7

The epidemiology of anxiety and panic disorders: An update. June, Suppl, 11–17

Treatment of panic disorder and agoraphobia with clonazepam. May, 238–242

Paraphrenia

Late-life paraphrenia: An organic delusional syndrome. Apr, 204–207

Personality Disorders

Assessment of DSM-III personality disorders: The importance of interviewing an informant. May, 261–263

Pharmacokinetics

Bioavailability of psychotropic drugs: Historical perspective and pharmacokinetic overview. Sept, Suppl, 6–15

Pharmacology

Pharmacologic probes of neurotransmitter systems in tardive dyskinesia: Implications for clinical management. Feb, 56–59

Pharmacologic treatment of phobic disorders. Sept, 445–452
The future of neuroleptic psychopharmacology. May, Suppl, 3–11
Pharmacotherapy
Antidepressant drug therapy for bulimia: Current status. July, 339–345
Early, targeted pharmacotherapeutic intervention in schizophrenia. May, Suppl, 23–29
Pharmacotherapeutic considerations in anxiety disorders. July, Suppl, 33–36
Pharmacotherapy of the panic disorders. June, Suppl, 27–32
Psychotropic medication in adolescents: A review. Aug, 400–408
Update on neuroreceptor mechanisms and their implication for the pharmacotherapy of affective disorders. Oct, Suppl, 13–18
Phencyclidine
Extended EMIT-DAU phencyclidine screen. Apr, 194–195
Improvement of phencyclidine-associated psychosis with ECT. Sept, 477–478
Phencyclidine in CSF and serum: A case of attempted filicide by a mother without a history of substance abuse. Aug, 428–429
Phenelzine
Phenelzine for chronic depression: A study of continuation treatment. July, 346–349
Phenelzine treatment of melancholia. Aug, 420–422
The DST as a predictor of acute response to treatment with ECT, chlorimipramine, amitriptyline, and phenelzine. Mar, 139–140
Urinary amine metabolite excretion in a patient with adrenergic hyperactivity state: Reaction to phenelzine withdrawal and combined treatment. Feb, 92–93
Phenothiazines
Response of tricyclic-induced jitteriness to a phenothiazine in two patients. Aug, 427
Phenytoin
A case of phenytoin toxicity possibly precipitated by trazodone. Feb, 89–90
Phobias
Pharmacologic treatment of phobic disorders. Sept, 445–452
Physostigmine
Physostigmine in alcohol withdrawal: A new clinical approach (letter). Oct, 530
Pindolol
Therapeutic effects of pindolol on behavioral disturbances associated with organic brain disease: A double-blind study. Aug. 423–426
Placebo Response
Early placebo response in anxious and depressed patients. May, 230–233
Plasma Levels
Plasma levels of cortisol, corticotropin, and β-endorphin in patients with major depression. Aug, 413–414
Relationship between dystonia and serum calcium levels. Aug, 418–419
The future of neuroleptic psychopharmacology. May, Suppl, 3–11
Tricyclic antidepressant plasma level monitoring: An improvement over the dose-response approach. Jan, Suppl, 24–30
Polydipsia
Captopril in the treatment of psychogenic polydipsia (letter). Feb, 99
Self-induced water intoxication: A comparison of 34 cases with matched controls. July, 368–370
Positron Emission Tomography
Brain imaging in the search for biological markers in affective disorder. Oct, Suppl, 7–10
Posttraumatic Stress Syndrome
Antidepressant treatment for posttraumatic stress disorder (PTSD) (letter). May, 275
Axis II character disorders in PTSD (letter with reply). Apr, 217
Premenstrual Syndrome
Premenstrual tension syndrome in rapid-cycling bipolar affective disorder. Aug, 415–417
Verapamil in the treatment of premenstrual syndrome: Case report. Apr, 213–214
Propranolol
Alprazolam as an adjunct to propranolol in anxious outpatients with stable angina pectoris. Jan, 8–11
Depressive symptoms in propranolol users. Sept, 453–457
Improvement in tardive dyskinesia and MMPI scores with propranolol (letter). Apr, 218–219
Protriptyline
Bethanechol chloride can reverse erectile and ejaculatory dysfunction induced by tricyclic antidepressants and mazindol: Case report. Apr, 210–211
Psychiatry
Introduction: New directions in biological psychiatry. Oct, Suppl, 3–5
Psychosexual Disturbances
Psychosexual disturbances in multiple personality: Characteristics, etiology, and treatment. Mar, 106–110
Psychosis
Acute psychosis in a patient receiving trimethoprim-sulfamethoxazole intravenously. May, 269–270
Antipsychotic drugs and the elderly. May, Suppl, 17–22
Evaluation of the need for prophylactic antiparkinsonian medication in psychotic patients treated with neuroleptics. Mar, 114–116
Improvement of phencyclidine-associated psychosis with ECT. Sept, 477–478
Monosymptomatic hypochondriacal psychosis manifesting as delusions of infestation: Case studies of treatment with haloperidol. Apr, 188–190
The future of neuroleptic psychopharmacology. May, Suppl, 3–11
Utility of neuroleptic blood levels in the treatment of acute psychosis. Dec, 600–603
Psychosis, Postpartum
Postpartum psychosis (letter with reply). June, 331
Psychostimulants: See also specific drugs
Psychostimulants and schizophrenic relapse (letter). Jan, 48
Psychotropics
Bioavailability of psychotropic drugs: Historical perspective and pharmacokinetic overview. Sept, Suppl, 6–15
Clinical relevance of the bioavailability/bioequivalence controversy. Sept, Suppl, 3–5
Determination of bioequivalence of psychotropic drugs and concerns involving product interchange. Sept, Suppl, 28–32
Psychotropic blood levels: A guide to clinical response. Sept, Suppl, 16–19
Psychotropic medication in adolescents: A review. Aug, 400–408
The significance of pharmacodynamic measurements in the assessment of bioavailability and bioequivalence of psychotropic drugs using CEEG and dynamic brain mapping. Sept, Suppl, 20–27
Purpura
Psychogenic purpura, idiopathic thrombocytopenic purpura, and platelet dysfunction in the same patient. July, 386–387
Race
The effect of alcoholism on membrane lithium transport. July, 350–353
Rapid Mood Cycling
Danazol and the rapid-cycling patient (letter). Mar, 153–154
Rapid Tranquilization
Rapid tranquilization: A comparison of thiothixene with loxapine. June, 294–297
Receptor Studies
Central dopaminergic and noradrenergic receptor blockade in a patient with neuroleptic malignant syndrome. June, 320–321
Pharmacologic modification of serotonergic function: Drugs for the study and treatment of psychiatric and other disorders. Apr, Suppl, 4–8
Update on neuroreceptor mechanisms and their implication for the pharmacotherapy of affective disorders. Oct, Suppl, 13–18
Use of serotonergic agents in the clinical assessment of central serotonin function. Apr, Suppl, 9–15
Relapse
Drug holidays and serum haloperidol levels in schizophrenic patients. July, 373–374
Renal Failure
Renal disease and dysfunction in two patients with anorexia nervosa. Aug, 433–434
Research Diagnostic Criteria
Application of Research Diagnostic Criteria and International Classification of Diseases to case vignettes. Feb, 78–80
Reserpine
A case of progressive hemichorea responsive to high-dose reserpine. Mar, 149–150
Rhabdomyolysis
A case of massive rhabdomyolysis following molindone administration. Dec, 607–608
Schizoaffective Disorders
Medication-induced somnambulism in a patient with schizoaffective disorder. Oct, 523–524
Schizophrenia
A comparison of parenteral loxapine and haloperidol in hostile and aggressive acutely schizophrenic patients. Mar, 126–129
Antipsychotic drugs and the elderly. May, Suppl, 17–22
Depressive symptoms in acute schizophrenic inpatients (letter wtih reply). June, 329
Drug holidays and serum haloperidol levels in schizophrenic patients. July, 373–374
Early, targeted pharmacotherapeutic intervention in schizophrenia. May, Suppl, 23–29
Mesoridazine and thioridazine: Clinical effects and blood levels in refractory schizophrenics. July, 375–379
Myelin basic protein antibodies in catatonic schizophrenia. Jan, 26–28
Psychostimulants and schizophrenic relapse (letter). Jan, 48
Relapse in chronic schizophrenics treated with fluphenazine decanoate is associated with low serum neuroleptic levels. May, 247–248
Suicide in schizophrenia (letter with reply). Nov, 570
Schizophrenia, Late Onset
Late-life paraphrenia: An organic delusional syndrome. Apr, 204–207
Screening Tests
Extended EMIT-DAU phencyclidine screen. Apr, 194–195
Screening for tardive dyskinesia. Feb, 75–77
Seizures
Complex partial seizures in a patient receiving trazodone. June, 318–319
Panic attacks and psychomotor seizures following right temple lobectomy (letter). Apr, 219
Self-Induced Water Intoxication
Self-induced water intoxication: A comparison of 34 cases with matched controls. July, 368–370
Serotonergic Function
Introduction: Serotonin neurochemistry and psychopharmacology in 1986. Apr, Suppl, 3
Modulation of ethanol intake by serotonin uptake inhibitors. Apr, Suppl, 16–22
Pharmacologic modification of serotonergic function: Drugs for the study and treatment of psychiatric and other disorders. Apr, Suppl, 4–8
Therapeutic effects of serotonin uptake inhibitors in depression. Apr, Suppl, 23–35
Use of serotonergic agents in the clinical assessment of central serotonin function. Apr, Suppl, 9–15
Serotonin Irritation Syndrome
Ill winds, sad days, and the body electric: A new role for the environment in behavior? (letter with reply). July, 392
Reversibility of serotonin irritation syndrome with atmospheric anions. Mar, 141–143
The serotonin irritation syndrome: A new clinical entity? Jan, 22–25

Sexual Dysfunction
Sexual dysfunction secondary to cocaine abuse in two patients. July, 384–385

Side Effects: See also specific drugs
A case of trazodone-induced ventricular tachycardia. July, 388–389
A comparison of the effects of trazodone and amitriptyline on skills performance by geriatric subjects. May, 252–254
Bethanechol chloride can reverse erectile and ejaculatory dysfunction induced by tricyclic antidepressants and mazindol: Case report. Apr, 210–211
Cimetidine and mental status changes (letter). Feb, 99–100
Evaluation of the need for prophylactic antiparkinsonian medication in psychotic patients treated with neuroleptics. Mar, 114–116
Lithium associated with psoriasis (letter). June, 330
Low-sedation potential of buspirone compared with alprazolam and lorazepam in the treatment of anxious patients: A double-blind study. Aug, 409–412
Monoamine oxidase inhibitor-induced speech blockage. Dec, 604
Neuroleptic drug-induced coagulopathy: Mechanism of reaction and duration of effect. Jan, 35–37
Report of a patient with lithium-related alopecia and psoriasis. Apr, 212
Response of tricyclic-induced jitteriness to a phenothiazine in two patients. Aug, 427
Successful treatment of lithium-induced acne (letter). Jan, 48
Tics with combined thioridazine-methylphenidate therapy: Case report. Jan, 44–45

Sleep Disorders
Comparative effects of limbitrol and amitriptyline on sleep efficiency and architecture. Dec, 587–591
Medication-induced somnambulism in a patient with schizoaffective disorder. Oct, 523–524
Sleep-disordered breathing in normal and pathologic aging. Oct, 499–503

Somatoform Disorder
Psychogenic purpura, idiopathic thrombocytopenic purpura, and platelet dysfunction in the same patient. July, 386–387

Stimulants
The stimulant challenge test in depression. Nov, 538–543

Suicidal Behavior/Ideation
Response of energy and suicidal ideation to ECT. Jan, 31–32

Suicide
Suicide in schizophrenia (letter with reply). Nov, 570

Sulfonamides
Acute psychosis in a patient receiving trimethoprim-sulfamethoxazole intravenously. May, 269–270

Sulindac
Failure of sulindac to increase serum lithium levels. Jan, 33–34

Tardive Dyskinesia
Exacerbation of tardive dyskinesia by Joseph disease. June, 315–316
Improvement in tardive dyskinesia and MMPI scores with propranolol (letter). Apr, 218–219
Pharmacologic probes of neurotransmitter systems in tardive dyskinesia: Implications for clinical management. Feb, 56–59
Screening for tardive dyskinesia. Feb, 75–77
Suppression of tardive dyskinesia with amoxapine: Case report. Mar, 148
Tremor and tardive dyskinesia. Sept, 461–464

Thioridazine
Behavioral changes following generic thioridazine (letter). May, 277–278
Haloperidol versus thioridazine in the treatment of behavioral symptoms in senile dementia of the Alzheimer's type: Preliminary findings. June, 310–312
Mesoridazine and thioridazine: Clinical effects and blood levels in refractory schizophrenics. July, 375–379
Tics with combined thioridazine-methylphenidate therapy: Case report. Jan, 44–45

Thiothixene
Rapid tranquilization: A comparison of thiothixene with loxapine. June, 294–297

Third Party Payment
Reflections of a CHAMPUS-APA peer reviewer. Feb, 71–74

Thyroid Disorders
Progressive dementia associated with thyroid disease (letter). Feb, 100

Tourette's Syndrome
A case of Tourette's syndrome with symptoms of attention deficit disorder treated with desipramine. Sept, 478–479
Anorexia nervosa in a young man with Tourette's syndrome. June, 324–326
Tourette's syndrome and attention deficit disorder (letter). June, 330

Toxicity
A case of erythromycin-induced carbamazepine toxicity. Mar, 147
A case of phenytoin toxicity possibly precipitated by trazodone. Feb, 89–90

Toxicologic Analysis
Extended EMIT-DAU phencyclidine screen. Apr, 194–195

Tranylcypromine
Tranylcypromine: Patterns and predictors of response. July, 380–382

Trazodone
A case of phenytoin toxicity possibly precipitated by trazodone. Feb, 89–90
A case of trazodone-induced ventricular tachycardia. July, 388–389
A comparison of the effects of trazodone and amitriptyline on skills performance by geriatric subjects. May, 252–254
Complex partial seizures in a patient receiving trazodone. June, 318–319
Drug treatment of panic disorder: The comparative efficacy of imipramine, alprazolam, and trazodone. Dec, 580–586
Improvement in organically disturbed behavior with trazodone treatment. Apr, 191–193
Trazodone in dementia (letter). Sept, 482
Trazodone overdose: Four years of experience from voluntary reports. Nov, 544–546

TRH Test
Psychiatric applications of thyroid tests. Jan, Suppl, 13–16

Triazolam
Triazolam overdose (letter). Jan, 50

Tricyclic Antidepressants
Mania induced by tricyclic-MAOI combination therapy in bipolar treatment-resistant disorder: Case reports. Jan, 40–41
Monoamine oxidase inhibitors and tricyclic antidepressants: Comparison of their cardiovascular effects. May, 225–229
Response of tricyclic-induced jitteriness to a phenothiazine in two patients. Aug, 427
Tricyclic antidepressant plasma level monitoring: An improvement over the dose-response approach. Jan, Suppl, 24–30
Tricyclic-resistant depression (letter with reply). July, 393

Trifluoperazine
Effective short-term treatment of generalized anxiety disorder with trifluoperazine. Apr, 170–174

Verapamil
Clonidine and verapamil in the treatment of mania (letter with reply). Nov, 570
Verapamil in the treatment of premenstrual syndrome: Case report. Apr, 213–214
Verapamil treatment of acute mania. Mar, 136–138

Yohimbine
Enhancement of ECT benefit by yohimbine. Oct, 508–510

Journal of Clinical Psychiatry

Author Index to Volume 47: January 1986 Through December 1986

Adler LW: Mixed bipolar disorder responsive to lithium and clonazepam (letter). Jan, 49–50
Agbayewa MO: EEG and CT scan in Alzheimer's disease (letter). Apr, 217–218
Ahokas A see Rimon R
Aiken B see Charney DS
Akhtar S see Doghramji K
Akhtar S, Byrne JP, Doghramji K: The demographic profile of borderline personality disorder. Apr, 196–198
Akiskal HS: Reviews of Fonagy P, Higgitt A: *Personality Theory and Clinical Practice*, Apr, 215; Robins E: *The Final Months: A Study of the Lives of 134 Persons Who Committed Suicide*, July, 390; Runyan WM: *Life Histories and Psychobiography: Explorations in Theory and Method*, Apr, 215; Soubrier JP, Vedrinne J (eds): *Depression & Suicide*, July, 390; Thompson K (ed): *Readings from Emile Durkheim*, July, 390; Wilmotte J, Mendlewicz J (eds): *New Trends in Suicide Prevention*, July, 390. See also **Placidi GF**
Albert MS see Jenike MA
Alexander DD see Alexander PE
Alexander PE, Alexander DD: Alprazolam treatment for panic disorders. June, 301–304
Alexander RC see Goldman LS
Allen A see Rosse RB
Allen AD: Reply to Miller AH, Silberstein C, Asnis GM, et al: Epstein-Barr virus infection and depression (letter). Oct, 529–530
Allen AD, Tilkian SM: Depression correlated with cellular immunity in systemic immunodeficient Epstein-Barr virus syndrome (SIDES). Mar, 133–135
Allen RE see Kramer BA
Altman see Weller MA
Alvarez WA see Freinhar JP; Johnson SB
Amen DG: Use of hypnosis in EPS-associated anxiety (letter). Feb, 98
Ananth J see Pratty JS
Andrews E, Bellard J, Walter-Ryan WG: Monosymptomatic hypochondriacal psychosis manifesting as delusions of infestation: Case studies of treatment with haloperidol. Apr, 188–190
Annable L see Beaudry P
Anniball JA, Kales JD, Tan TL: Anorexia nervosa in a young man with Tourette's syndrome. June, 324–326
Anseau M, Reynolds III CF, Kupfer DJ, Pouclet PF, Franck G, Dresse AE, Reznik M: Central dopaminergic and noradrenergic receptor blockade in a patient with neuroleptic malignant syndrome. June, 320–321
Aronson MD, Hafez H: A case of trazodone-induced ventricular tachycardia. July, 388–389
Asberg M, Eriksson B, Martensson B, Traskman-Bendz L, Wagner A: Therapeutic effects of serotonin uptake inhibitors in depression. Apr, Suppl, 23–35
Askinazi C, Weintraub RJ, Karamouz N: Elderly depressed females as a possible subgroup of patients responsive to methylphenidate. Sept, 467–469
Asnis G see Eisenberg J
Asnis GM see Miller AH
Aulakh CS see Murphy DL
Avery DH see Dunner DL
Baer L see Carey Jr RJ
Ballenger JC: Pharmacotherapy of the panic disorders. June, Suppl, 27–32. See also **Lydiard RB**
Banner A see Weddington Jr WW
Barban L see Putnam FW
Barone JA, Byerly WG: Determination of bioequivalence of psychotropic drugs and concerns involving product interchange. Sept, Suppl, 28–32
Barouche F see Fleve RR
Bauer J see Ostrow DG
Bayless J see Nasrallah HA
Beaudry P, Fontaine R, Chouinard G, Annable L: Clonazepam in the treatment of patients with recurrent panic attacks. Feb, 83–85
Beck EA see Fey MF
Beckett A, Fishman SM, Rosenbaum JF: Clonazepam blockade of spontaneous and CO_2 inhalation-provoked panic in a patient with panic disorder. Sept, 475–476
Beigel Y see Modai I
Bellard J see Andrews E
Belmaker RH see Zohar J
Benezech M see Yesavage JA
Benson F see Miller BL
Berkowitz HL: Tricyclic-resistant depression (letter with reply). July, 393
Berlanga C see de la Fuente JR
Berman SR see Hoch CC
Berne C see Rosmark B
Berrettini WH: A case of erythromycin-induced carbamazepine toxicity. Mar, 147
Bertrand S see Ghadirian AM
Biederman J see Hoge SK
Bilikiewicz A see Stojek A
Black DW, Winokur G: Reply to Sorenson SB, Knight K: Suicide in schizophrenia (letter). Nov, 570–571
Blanchard C see Zusky P
Blatt M see Mendels J
Blum A: Is postpsychotic depression a primary affective disorder? (letter with reply). Sept, 482
Bogard B see Schuckit MA
Bourgeois M see Yesavage JA
Brandon S: Review of Meier JH (ed): *Assault Against Children—Why It Happens, How To Stop It.* Mar, 151
Bresolin LB see Ostrow DG
Brotman AW see Sachs GS
Brotman AW, Farhadi AM, Gelenberg AJ: Verapamil treatment of acute mania. Mar, 136–138
Brotman AW, Stern TA, Brotman DL: Renal disease and dysfunction in two patients with anorexia nervosa. Aug, 433–434
Brotman DL see Brotman AW
Browne JL, Hart RR: Exacerbation of tardive dyskinesia by Joseph disease. June, 315–316
Buchsbaum MS: Brain imaging in the search for biological markers in affective disorder. Oct, Suppl, 7–10
Burch Jr EA, Goldschmidt TJ, Schwartz BD: Drug intake and the dexamethasone suppression test. Mar, 144–146
Burke WJ see Zorumski CF
Burnett GB see Evans DL
Burns M, Moskowitz H, Jaffe J: A comparison of the effects of trazodone and amitriptyline on skills performance by geriatric subjects. May, 252–254
Bursten B: Review of Neuberger EH and Bourne R (eds): *Unhappy Families: Clinical and Research Perspectives on Family Violence.* Feb, 97
Burton HB: "Antipsychotic" or "neuroleptic" (letter). July, 392
Byerly WG see Barone JA
Byrne JP see Akhtar S
Cantor C: Carbamazepine and ECT: A paradoxical combination (letter). May, 276–277
Cantwell DP: Review of Menolascino FJ, Stark JA (eds): *Handbook of Mental Illness in the Mentally Retarded.* August, 435
Carey Jr RJ, Baer L, Jenike MA, Minichiello WE, Schwartz C, Regan NJ: MMPI correlates of obsessive-compulsive disorder. July, 371–372
Carpenter Jr W: Early, targeted pharmacotherapeutic intervention in schizophrenia. May, Suppl, 23–29
Carroll BJ: Informed use of the dexamethasone suppression test. Jan, Suppl, 10–12
Casat CD, Wilson III DC: Tics with combined thioridazine-methylphenidate therapy: Case report. Jan, 44–45
Cassano GB see Placidi GF
Cassem NH see Woods SW
Castaneda R, Franco H: Epidemiology of borderline personality disorder (letter with reply). Dec, 611–612
Cavanaugh SVA, Elliott RL: Review of Broome A, Wallace L (eds): *Psychology and Gynaecological Problems.* July, 390–391
Chamberlain BC: Review of Baruch G, Brooks-Gunn G (eds): *Women In Mid-Life.* May, 272–273
Chapman S see Nasrallah HA
Charney DS, Woods SW, Goodman WK, Rifkin B, Kinch M, Aiken B, Quadrino LM, Heninger GR: Drug treatment of panic disorder: The comparative efficacy of imipramine, alprazolam, and trazodone. Dec, 580–586
Chaudry DR see Noyes Jr R
Chernoff RW see Mendels J
Chien CP see Koo JYM
Chouinard G see Beaudry P
Clower CG: DST has no predictive ability for acute response to ECT (letter with reply). Dec, 612
Cocores JA, Dackis CA, Gold MS: Sexual dysfunction secondary to cocaine abuse in two patients. July, 384–385
Coffman JA see Nasrallah HA
Cohn JB, Wilcox CS: Low-sedation potential of buspirone compared with alprazolam and lorazepam in the treatment of anxious patients: A double-blind study. Aug, 409–412
Coleman JH: Review of Bartholini G, Lloyd KG, Morselli PL (eds): *GABA and Mood Disorders: Experimental and Clinical Research.* Nov, 569
Colon EA: Review of Dorfman W, Cristofar L (eds): *Psychosomatic Illness Review.* Dec, 610
Conn DK see Murray GB

Coons PM, Milstein V: Psychosexual disturbances in multiple personality: Characteristics, etiology, and treatment. Mar, 106–110
Copeland PM, Herzog DB: Non-bulimia: Food regurgitation in a patient with self-diagnosed bulimia. June, 317–318
Corenthal C see Zimmerman M
Couch L see McMillan DE
Coyle J see Jayaram G
Coyle JT see Joshi PK
Cummings JL see Miller BL
Cunningham CJ see Hughes PL
Cygielman G see Modai I
D'Mello DA, Nasrallah HA: Suppression of tardive dyskinesia with amoxapine: Case report. Mar, 148
Dackis CA see Cocores JA; Gold MS
Darko D see Giassman JN
Daul G see Ragan Jr FA
David AS see Keshaven MS
Davis CM see Ereshefsky L
Davis GC see Mellman TA
Davis JM see Ostrow DG
De Antonio M see Zetin M
de le Fuente JR, Berlanga C, Leon-Andrade C: Mania induced by tricyclic-MAOI combination therapy in bipolar treatment-resistant disorder: Case reports. Jan, 40–41
De Leo D see Magni G
Dealy RS see Spiker DG
Desai P see Ostrow DG
Diamond RJ: Review of Allen CK: *Occupational Therapy for Psychiatric Diseases: Measurement and Management of Cognitive Disabilities.* Aug, 435–436
Diaz-Cabal R, Pearlman C, Kawecki A: Hyperthyroidism in a patient with agitated depression: Resolution after electroconvulsive therapy. June, 322–323
Dilsaver SC, White K: Affective disorders and associated psychopathology: A family history study. Apr, 162–169
DiMarzio L see Price WA
Doddi SR see Siris SG
Doghramji K see Akhtar S
Doghramji K, Akhtar S: Reply to Castaneda R, Franco H: Epidemiology of borderline personality disorder (letter). Dec, 612
Domingo DV see Noyes Jr R
Dominguez RA, Goldstein BJ, Jacobson AF, Steinbook RM: Comparative efficacy of estazolam, flurazepam, and placebo in outpatients with insomnia. July, 362–365
Donnelly RF see Pande AC
Dorn JM: A case of phenytoin toxicity possibly precipitated by trazodone. Feb, 89–90
Doro JM see Mermel LA
Dorus W see Ostrow DG
Dresse AE see Ansseau M
Dreyfuss D, Shader RI, Harmatz JS, Greenblatt DJ: Kinetics and dynamics of single doses of oxazepam in the elderly: Implications of absorption rate. Oct, 511–514
Dubin WR, Weiss KJ: Rapid tranquilization: A comparison of thiothixene with loxapine. June, 294–297
Dunner DL see Loebel AD
Dunner DL, Ishiki D, Avery DH, Wilson LG, Hyde TS: Effect of alprazolam and diazepam on anxiety and panic attacks in panic disorder: A controlled study. Sept, 458–460
Dunner FJ see Nasrallah HA
Durr MJ see Mendels J
Edwards HB: The multiple dangers of smoking (letter). Apr, 218
Edwards J see Sabelli HC
Edwards NB: Review of Mangan GL, Golding JF: *The Psychopharmacology of Smoking.* July, 391
Elsenberg J, Asnis G: Are antidepressant trials too short? A case report. Jan, 38–39
Elliot C see Zusky P
Elliott RL see Cavanaugh SVA
Ereshefsky L, Jann MW, Saklad SR, Davis CM: Bioavailability of psychotropic drugs: Historical perspective and pharmacokinetic overview. Sept, Suppl, 6–15
Eriksson B see Asberg M
Evans DL, Strawn SK, Haggerty Jr JJ, Garbutt JC, Burnett GB, Pedersen CA: Appearance of mania in drug-resistant bipolar depressed patients after treatment with L-triiodothyronine. Oct, 521–522
Evenson RC see Jos CJ
Extein I, Gold MS: Psychiatric applications of thyroid tests. Jan, Suppl, 13–16
Falk WE see Renmer HI
Farhadi AM see Brotman AW; Sachs GS
Fawcett J see Sabelli HC
Feureisen S see Zetin M
Fey MF, Beck EA: Psychogenic purpura, idiopathic thrombocytopenic purpura, and platelet dysfunction in the same patient. July, 386–387
Fieve R see Zetin M
Fieve RR, Goodnick PJ, Peselow ED, Barouche F, Schlegel A: Pattern analysis of antidepressant response to fluoxetine. Nov, 560–562
Fishman SM see Beckett A
Fody EP see McMillan DE
Folks DG see Parker PE
Fontaine R see Beaudry P
Foster D see Simpson DM
Foster HM, Narasimhachari N: Phencyclidine in CSF and serum: A case of attempted filicide by a mother without a history of substance abuse. Aug, 428–429
Fox HA see Rosen AM
Franck G see Ansseau M
Franco H see Castaneda R
Freinhar JP see Johnson SB
Freinhar JP, Alvarez WA: Clonazepam treatment of organic brain syndromes in three elderly patients. Oct, 525–526
Friedman B see Kramer BA
Friedman JH: A case of progressive hemichorea responsive to high-dose reserpine. Mar, 149–150
Friedman MJ see Griffin SJ
Fudenberg HH see Singh VK
Fuller RW: Pharmacologic modification of serotonergic function: Drugs for the study and treatment of psychiatric and other disorders. Apr, Suppl, 4–8
Gamble DE, Peterson LG: Trazodone overdose: Four years of experience from voluntary reports. Nov, 544–546
Garber D see Zetin M
Garbutt JC see Evans DL
Garey RE see Ragan Jr FA
Garrick NA see Murphy DL
Gauthier S see Ghadirian AM
Gelenberg AJ see Brotman AW; Sachs GS
Gentil V: Review of Kemali D, Racagni G (eds): *Chronic Treatments in Neuropsychiatry, Volume 40 of Advances in Biochemical Psychopharmacology.* Aug, 436
Gerbino L see Vital-Herne J
Gerner RH see Giilin MJ
Gershon S see Ortiz A; Pohl R
Ghadirian AM, Gauthier S, Bertrand S: Anxiety attacks in a patient with a right temporal lobe meningioma. May, 270–271
Ghadirian AM, Lalinec-Michaud M: Report of a patient with lithium-related alopecia and psoriasis. Apr, 212
Giannini AJ: Reply to Miller L: Ill winds, sad days, and the body electric: A new role for the environment in behavior? (letter). July, 392–393. See also **Price WA**
Giannini AJ, Houser WL, Kerr L: Clonidine and verapamil in the treatment of mania (letter with reply). Nov, 570
Giannini AJ, Jones BT, Loiselle RH: Reversibility of serotonin irritation syndrome with atmospheric anions. Mar, 141–143
Giannini AJ, Malone DA, Piotrowski TA: The serotonin irritation syndrome: A new clinical entity? Jan, 22–25
Gillin JC see Giassman JN
Gillin MJ, Gerner RH: The dexamethasone suppression test and response to somatic treatment: A review. Jan, 16–21
Gklouzepas J see Manos N
Glassman JN, Darko D, Gillin JC: Medication-induced somnambulism in a patient with schizoaffective disorder. Oct, 523–524
Glazer WM see Hansen TE
Goff DC: The stimulant challenge test in depression. Nov, 538–543
Gold MS see Cocores JA; Extein I
Gold MS, Dackis CA: Role of the laboratory in the evaluation of suspected drug abuse. Jan, Suppl, 17–23
Goldberg RL see Goldstein DM
Goldman LS, Alexander RC, Luchins DJ: Monoamine oxidase inhibitors and tricyclic antidepressants: Comparison of their cardiovascular effects. May, 225–229
Goldschmidt TJ see Burch Jr EA
Goldstein BJ see Dominguez RA
Goldstein DM, Goldberg RL: Monoamine oxidase inhibitor-induced speech blockage. Dec, 604
Goldstein JA: Captopril in the treatment of psychogenic polydipsia (letter), Feb, 99; Danazol and the rapid-cycling patient (letter), Mar, 153–154; Nonsteroidal anti-inflammatory drugs and panic disorder (letter), May, 277; Treatment of chronic Epstein-Barr virus disease with H_2 blockers (letter), Nov, 572
Goldman WK see Charney DS
Goodnick PJ see Fieve RR
Goodwin DW: Review of McHugh PR, Slavney PR: *The Perspectives of Psychiatry.* Sept, 480
Gottschalk LA: Clinical relevance of the bioavailability/bioequivalence controversy. Sept, Suppl, 3–5
Gray GE, Leong GB: Serum folate levels in U.S. psychiatric inpatients (letter). Feb, 98–99
Greden JF see Grunhaus L
Greenberg WM: Are benzodiazepines anticholinergic? (letter with reply). July, 393
Greenblatt DJ see Dreyfuss D
Greendyke RM, Kanter DR: Therapeutic effects of pindolol on behavioral disturbances associated with organic brain disease: A double-blind study. Aug, 423–426
Greenlee RA: The *Journal* is accomplishing its mission (letter). Apr, 217
Grey P: Early diagnosis of neuroleptic malignant syndrome (letter). Mar, 154
Griffin SJ, Friedman MJ: Depressive symptoms in propranolol users. Sept, 453–457
Grillo Jr RA, Olsen NH: Amnesia as a presenting symptom in subacute bacterial endocarditis. July, 383–384
Grover D, Yeragani VK, Keshaven MS: Improvement of phencyclidine-associated psychosis with ECT. Sept, 477–478
Grunhaus L, Rabin D, Greden JF: Simultaneous panic and depressive disorder: Response to antidepressant treatment. Jan, 4–7
Gunther J see Jenike MA
Guroff JJ see Putnam FW
Gusovsky F see Sabelli HC
Hachinski V see Wade J
Hafez H see Aronson MD
Haggerty Jr JJ see Evans DL
Hall KS see Siris SG
Halonen P see Rimon R
Hanin I see Spiker DG
Hansen TE, Glazer WM, Moore DC: Tremor and tardive dyskinesia. Sept, 461–464
Harmatz JS see Dreyfuss D
Harris SE: Antidepressant treatment for posttraumatic stress disorder (PTSD) (letter). May, 275
Harrison RH see McMillan DE
Harrison W see McGrath PJ
Harrison W, Rabkin J, Stewart JW, McGrath PJ, Tricamo E, Quitkin F: Phenelzine for chronic depression: A study of continuation treatment. July, 346–349
Hart RR see Browne JL

Heinze G, Sanchez A: Overdose with moclobemide (letter). Aug, 438
Heiser JF see Sramek JJ
Heller H see Jenike MA
Heninger GR see Charney DS
Herzog DB see Copeland PM
Hirschowitz J see Scharf MB
Hite SA see Ragan Jr FA
Hoch CC, Reynolds III CF, Kupfer DJ, Houck PR, Berman SR, Stack JA: Sleep-disordered breathing in normal and pathologic aging. Oct, 499–503
Hoge SK, Biederman J: A case of Tourette's syndrome with symptoms of attention deficit disorder treated with desipramine. Sept, 478–479
Hollister LE: Pharmacotherapeutic considerations in anxiety disorders. June, Suppl, 33–36
Holmgren S see Rosmark B
Holt RJ see Zengotita HE
Hoon P: Review of DeFries Z, Friedman RC, Corn R (eds): *Sexuality: New Perspectives.* Sept, 480–481
Houck PR see Hoch CC
House JD see Kronfol Z
Houser WL see Giannini AJ
Howell EF see Lydiard RB
Hsu LKG, Starzynski JM: Mania in adolescence. Dec, 596–599
Hudson JI see Pope Jr HG
Huey LY see Zetin M
Huffer V see Mendels J
Hughes JR: ECT during and after the neuroleptic malignant syndrome: Case report. Jan, 42–43
Hughes PL, Wells LA, Cunningham CJ: The dexamethasone suppression test in bulimia before and after successful treatment with desipramine. Oct, 515–517
Hyde TS see Dunner DL; Loebel AD
Insel TR see Zohar J
Ishiki D see Dunner DL
Itil KZ see Itil TM
Itil TM, Itil KZ: The significance of pharmacodynamic measurements in the assessment of bioavailability and bioequivalence of psychotropic drugs using CEEG and dynamic brain mapping. Sept, Suppl, 20–27
Jacobson AF see Dominguez RA
Jaffe J see Burns M
Jann MW see Ereshefsky L
Javaid JJ see Sabelli HC
Jayaram G, Coyle J, Tune L: Relapse in chronic schizophrenics treated with fluphenazine decanoate is associated with low serum neuroleptic levels. May, 247–248
Jefferson JW: Is folate deficiency a side effect of lithium therapy? (letter). May, 276
Jeffries H see Sabelli HC
Jenike MA see Carey Jr RJ
Jenike MA, Albert MS, Heller H, LoCastro S, Gunther J: Combination therapy with lecithin and ergoloid mesylates for Alzheimer's disease. May, 249–251
Jewell SW see Rich CL
Jewett C see Zetin M
Jobe TH see Weller MA
Joffe RT, Post RM, Uhde TW: Effect of carbamazepine on body weight in affectively ill patients. June, 313–314
Johnson SB, Alvarez WA, Freinhar JP: A case of massive rhabdomyolysis following molindone administration. Dec, 607–608
Jonas JM see Linden RD
Jones BT see Giannini AJ
Jos CJ, Evenson RC, Mallya AR: Self-induced water intoxication: A comparison of 34 cases with matched controls. July, 368–370
Joseph AB: A hypergraphic syndrome of automatic writing, affective disorder, and temporal lobe epilepsy in two patients, May, 255–257; Cotard's syndrome in a patient with coexistent Capgras' syndrome, syndrome of subjective doubles, and palinopsia, Dec, 605–606; Koro: Computed tomography and brain electrical activity mapping in two patients, Aug, 430–432
Joseph AB, O'Leary DH: Brain atrophy and interhemispheric fissure enlargement in Cotard's syndrome. Oct, 518–520
Joshi PK, Maisami M, Coyle JT: Prospective study of intake procedures in a child psychiatry clinic. Mar, 111–113
Kabadi UM see Mermel LA
Kales JD see Annibali JA
Kane JM, Woerner M, Sarantakos S: Depot neuroleptics: A comparative review of standard, intermediate, and low-dose regimens. May, Suppl, 30–33
Kanter DR see Greendyke RM
Kao PC see Lin SC
Karamouz N see Askinazi C
Kato M see Kitamura T
Katon W: Panic disorder: Epidemiology, diagnosis, and treatment in primary care. Oct, Suppl, 21–27
Katz IR see Vital-Herne J
Katz P: Review of Manson SM, Dinges NC, Grounds LM, et al: *Psychosocial Research on American Indian and Alaska Native Youth: An Indexed Guide to Recent Dissertations.* Jan, 46
Kawecki A see Diaz-Cabal R
Kay SR see Vital-Herne J
Kerr L see Giannini AJ
Keshaven MS see Grover D
Keshaven MS, David AS, Narayanen HS, Satish P: "On-Off" phenomena and manic-depressive mood shifts: Case reports. Feb, 93–94
Khouri P: Review of Committee on Research, Group for the Advancement of Psychiatry (GAP): *Research and the Complex Causality of the Schizophrenias.* Mar, 151–152
Kinch M see Charney DS
Kitamura T, Shima S, Sakio E, Kato M: Application of Research Diagnostic Criteria and International Classification of Diseases to case vignettes. Feb, 78–80
Klerman GL: Current trends in clinical research on panic attacks, agoraphobia, and related anxiety disorders, June, Suppl, 37–39; Introduction, June, Suppl, 3
Knight K see Sorenson SB
Koehler-Troy C, Strober M, Malenbaum R: Methylphenidate-induced mania in a prepubertal child. Nov, 566–567
Koo JYM, Chien CP: Coma following ECT and intravenous droperidol: Case report, Feb, 94–95; Reply to Lee BS: Possibility of hyperpyrexia with antipsychotic and anticholinergic drugs (letter), Nov, 571
Kores RC: Review of Nigl AJ: *Biofeedback and Behavioral Strategies in Pain Treatment.* Aug, 436
Kourany RFC: Review of Winnicott DW: *Deprivation and Delinquency.* May, 274
Krajewski TF see Mendels J
Kramer BA, Allen RE, Friedman B: Atropine and glycopyrrolate as ECT preanesthesia. Apr, 199–200
Kravitz H see Sabelli HC
Kronfol Z: Reply to Wolf JM: Elevated blood neutrophil concentration in mania (letter). June, 331
Kronfol Z, Turner R, House JD, Winokur G: Elevated blood neutrophil concentration in mania. Feb, 63–65
Kupfer DJ: Introduction: New directions in biological psychiatry. Oct, Suppl, 3–5. See also **Ansseau M; Hoch CC; Spiker DG**
Kurkjian HT: Review of Gartley CG (ed): *Managing Incontinence.* Nov, 568
Lago C see Rosmark B
Lalinec-Michaud M see Ghadirian AM
Laraia MT see Lydiard RB
Larocca F: Review of Garner DM, Garfinkel PE (eds): *Handbook of Psychotherapy for Anorexia Nervosa and Bulimia.* Jan, 47
Larrieu-Arguille R see Yesavage JA
Lavrentiadis G see Manos N
Lawria MO see Naranjo CA
Lazzerini F see Placidi GF
Lee BS: Possibility of hyperpyrexia with antipsychotic and anticholinergic drugs (letter with reply). Nov, 571
Lehman AF: Review of Talbott JA (ed): *The Chronic Mental Patient— Five Years Later.* Feb, 96
Lenzi A see Placidi GF
Leon-Andrade C see de le Fuente JR
Leong GB see Gray GE
Lerer B: Reply to Giannini AJ, Houser WL, Kerr L: Clonidine and verapamil in the treatment of mania (letter). Nov, 570
Lerner Y: Reply to Rifkin A: Depressive symptoms in acute schizophrenic inpatients (letter). June, 329
Lesser IM, Rubin RT: Diagnostic considerations in panic disorders. June, Suppl, 4–10
Lewis DA, Nasrallah HA: Mania associated with electroconvulsive therapy. July, 366–367
Licamele WL, O'Leary JH: Tourette's syndrome and attention deficit disorder (letter). June, 330
Lichstein M see Scharf MB
Lin SC, Maruta T, Newman DC, Kao PC: Plasma levels of cortisol, corticotropin, and β-endorphin in patients with major depression. Aug, 413–414
Linden RD, Pope Jr HG, Jonas JM: Pathological gambling and major affective disorder: Preliminary findings. Apr, 201–203
Linet LS: Mysterious MAOI hypertensive episodes. Nov, 563–565
LoCastro S see Jenike MA
Loebel AD, Hyde TS, Dunner DL: Early placebo response in anxious and depressed patients. May, 230–233
Loiselle RH see Giannini AJ; Price WA
Lou P see Zusky P
Lucas MJ see Steele C
Luchins DJ see Goldman LS
Lunsky LL: Review of Falloon IRH and others: *Family Management of Schizophrenia: A Study of Clinical, Social, Family, and Economic Benefits.* July, 391
Luther JS see Wall M
Lux WE see Rosse RB
Lydiard RB: Reply to Berkowitz HL: Tricyclic-resistant depression (letter). July, 393
Lydiard RB, Laraia MT, Howell EF, Ballenger JC: Can panic disorder present as irritable bowel syndrome? Sept, 470–473
Magni G, Schifano F, De Leo D: Low utility of the CSI in depressed elderly patients with medical disturbances (letter). May, 275
Maisami M see Joshi PK
Malenbaum R see Koehler-Troy C
Mallya AR see Jos CJ
Mallya G: Review of Guy W, Ban TA (eds): *The AGP System.* Nov, 569
Malone DA see Giannini AJ
Manos N: Reply to McEvoy JP: Neuroleptic dose and the need for prophylactic anticholinergic drugs (letter). Dec, 611
Manos N, Lavrentiadis G, Gklouzepas J: Evaluation of the need for prophylactic antiparkinsonian medication in psychotic patients treated with neuroleptics. Mar, 114–116
Manschreck TC see Zusky P
Marder SR see Van Putten T
Martensson B see Asberg M
Maruta T see Lin SC
Mavissakalian M, Michelson L: Agoraphobia: Relative and combined effectiveness of therapist-assisted *in vivo* exposure and imipramine. Mar, 117–122
Max P see Pande AC
May WT: Review of Levant RF, Shlien JM (eds): *Client-Centered Therapy and the Person-Centered Approach: New Directions in Theory, Research, and Practice,* Jan, 46
McAllister TW see Price TRP
McAllister TW, Price TRP: Clinical and DST response to bilateral sinusoidal but not to unilateral brief-pulse ECT. Nov, 557–559
McCalley-Whitters M see Nasrallah HA
McEvoy JP: Neuroleptic dose and the need for prophylactic anticholinergic drugs (letter with reply). Dec, 611
McGrath PJ see Harrison W

McGrath PJ, Stewart JW, Harrison W, Wager S, Quitkin FM: Phenelzine treatment of melancholia. Aug, 420–422

McMillan DE, Fody EP, Couch L, Harrison RH, Newton JEO, Reese WG: Drug holidays and serum haloperidol levels in schizophrenic patients. July, 373–374

Mellman TA, Davis GC: Reply to Sheeley WF: Axis II character disorders in PTSD (letter). Apr, 217

Mehmed AS see Mendels J

Mendels J, Chernoff RW, Blatt M: Alprazolam as an adjunct to propranolol in anxious outpatients with stable angina pectoris. Jan, 8–11

Mendels J, Krajewski TF, Huffer V, Taylor RJ, Secunda S, Schless A, Sebastian JA, Semchyshyn G, Durr MJ, Mehmed AS, Whyte A: Effective short-term treatment of generalized anxiety disorder with trifluoperazine. Apr, 170–174

Mendels J, Schless AP: Comparative efficacy of alprazolam, imipramine, and placebo administered once a day in treating depressed patients. July, 357–361

Merikangas KR see Weissman MM

Mermel LA, Doro JM, Kabr[illegible]UM: Acute psychosis in a patient receiving trimethoprim-sulfamethoxazole intravenously. May, 269–270

Michelson L see Mavissakalian M

Mickley D see Opler LA

Mielke D see Wall M

Miller AH, Silberstein C, Asnis GM, Munk G, Rubinson E, Spigland I, Norin A: Epstein-Barr virus infection and depression (letter with reply). Oct, 529

Miller L, Benson F, Cummings JL, Neshkes R: Late-life paraphrenia: An organic delusional syndrome. Apr, 204–207

Miller L: Ill winds, sad drugs, and the body electric: A new role for the environment in behavior? (letter with reply). July, 392

Mills M see Yesavage JA

Milstein V see Coons PM

Minichiello WE see Carey Jr RJ

Mitchell JE: Review of Emmett JW (ed): *Theory and Treatment of Anorexia Nervosa and Bulimia: Biomedical, Sociocultural, and Psychological Perspectives.* Jan, 46–47

Modai I: Reply to Clower CG: DST has no predictive ability for acute response to ECT (letter). Dec, 612

Modai I, Beigel Y, Gygelman G: Urinary amine metabolite excretion in a patient with adrenergic hyperactivity state: Reaction to phenelzine withdrawal and combined treatment. Feb, 92–93

Modai I, Rinsky H, Cygelman G: The DST as a predictor of acute response to treatment with ECT, chlorimipramine, amitriptyline, and phenelzine. Mar, 139–140

Moore DC see Hansen TE

Morrison RL see Sramek JJ

Moskowitz H see Burns M

Motet-Grigoras CN, Schuckit MA: Depression and substance abuse in handicapped young men. May, 234–237

Mueller EA see Murphy DL

Munetz MR, Schultz SC: Screening for tardive dyskinesia. Feb, 75–77

Munk G see Miller AH

Munoz R, Pitts Jr FN: Editorial. Jan, 3

Munoz RA: Reply to Smith Jr WF: Postpartum psychosis (letter), June, 331; Review of Perry S, Frances A, Clarkin J: *A DSM-III Case Book of Differential Therapeutics: A Clinical Guide to Treatment Selection,* Nov, 568–569

Murphy DL: Introduction: Serotonin neurochemistry and psychopharmacology in 1986. Apr, Suppl, 3

Murphy DL, Mueller EA, Garrick NA, Aulakh CS: Use of serotonergic agents in the clinical assessment of central serotonin function. Apr, Suppl, 9–15

Murray GB see Woods SW

Murray GB, Shea V, Conn DK: Electroconvulsive therapy for poststroke depression. May, 258–260

Naplerala K see Stojek A

Naranjo CA, Sellers EM, Lawrin MO: Modulation of ethanol intake by serotonin uptake inhibitors. Apr, Suppl, 16–22

Narasimhachari N see Foster HM

Narayanen HS see Keshaven MS

Nasr SJ see Weller MA

Nasrallah HA see D'Mello DA; Lewis DA

Nasrallah HA, Dunner FJ, McCalley-Whitters M, Smith RE: Pharmacologic probes of neurotransmitter systems in tardive dyskinesia: Implications for clinical management. Feb, 56–59

Nasrallah HA, Varney N, Coffman JA, Bayless J, Chapman S: Opiate antagonism fails to reverse post-ECT cognitive deficits. Nov, 555–556

Neil JF see Rich CL

Neshkes R see Miller BL

Newman DC see Lin SC

Newton JEO see McMillan DE

Norin A see Miller AH

Novac A: Improvement in tardive dyskinesia and MMPI scores with propranolol (letter). Apr, 218–219

Noyes Jr R, Chaudry DR, Domingo DV: Pharmacologic treatment of phobic disorders. Sept, 445–452

O'Brien JE see Pratty JS

O'Leary DH see Joseph AB

O'Leary JH see Licamele WL

Okonek A see Ostrow DG

Olsen NH see Grillo Jr RA

Opler LA see Vital-Herne J

Opler LA, Mickley D: Alprazolam in the treatment of bulimia (letter). Jan, 49

Orsulak PJ: Therapeutic monitoring of antidepressant drugs: Current methodology and applications. Oct, Suppl, 39–50

Ortiz A see Pohl R

Ortiz A, Gershon S: The future of neuroleptic psychopharmacology. May, Suppl, 3–11

Ostrow DG, Dorus W, Okonek A, Desai P, Bauer J, Bresolin LB, Davis JM: The effect of alcoholism on membrane lithium transport. July, 350–353

Pande AC, Max P, Donnelly RF: Lithium associated with psoriasis (letter). June, 330

Pandey G see Weller MA

Parker PE, Walter-Kyan WG, Pittman CS, Folks DG: Lithium treatment of hyperthyroidism and mania. May, 264–266

Parlour RR: Reflections of a CHAMPUS-APA peer reviewer. Feb, 71–74

Patterson WM: Review of Wall PD, Melzack R (eds): *Textbook of Pain.* Oct, 527

Peabody CA, Thornton JE, Tinklenberg JR: Progressive dementia associated with thyroid disease (letter). Feb, 100

Pearlman C see Diaz-Cabal R

Pedersen CA see Evans DL

Perr IN: Review of Reisner R: *Law and the Mental Health System: Civil and Criminal Aspects.* May, 273

Peselow ED see Fieve RR

Peterson LG see Gamble DE

Pfohl B see Zimmerman M

Phillipson M see Rich CL

Pies R: Atypical depression and seasonal energy syndrome (letter). Feb, 98

Pillard R: Review of De Cecco JP (ed): *Homophobia: An Overview.* Apr, 216

Piotrowski TA see Giannini AJ

Pitman RK: Review of Kelly WE (ed): *Post-Traumatic Stress Disorder and the War Veteran Patient.* Sept, 481

Pittman CS see Parker PE

Pitts Jr FN: Thanks to *Journal* reviewers (editorial). Apr, 187. See also **Munoz R**

Placidi GF, Lenzi A, Lazzerini F, Cassano GB, Akiskal HS: The comparative efficacy and safety of carbamazepine versus lithium: A randomized, double-blind 3-year trial in 83 patients. Oct, 490–494

Pohl R, Yeragani VK, Ortiz A, Ralsey Jr JM, Gershon S: Response of tricyclic-induced jitteriness to a phenothiazine in two patients. Aug, 427

Pollack MH see Sachs GS

Poncelet PF see Anseau M

Pope Jr HG see Linden RD

Pope Jr HG, Hudson JI: Antidepressant drug therapy for bulimia: Current status. July, 339–345

Post RM see Joffe RT; Putnam FW

Powell AL see Ragheb MA

Pratty JS, Ananth J, O'Brien JE: Relationship between dystonia and serum calcium levels. Aug, 418–419

Preskorn SH: Tricyclic antidepressant plasma level monitoring: An improvement over the dose-response approach. Jan, Suppl, 24–30

Price TRP see McAllister TW

Price TRP, McAllister TW: Response of depressed patients to sequential unilateral nondominant brief-pulse and bilateral sinusoidal ECT. Apr, 182–186

Price WA, DiMarzio L: Premenstrual tension syndrome in rapid-cycling bipolar affective disorder. Aug, 415–417

Price WA, Giannini AJ: Reply to Greenberg WM: Are benzodiazepines anticholinergic? (letter), July, 393; Triazolam overdose (letter), Jan, 50; Verapamil in the treatment of premenstrual syndrome: Case report, Apr, 213–214; Withdrawal dyskinesia following amoxapine therapy (letter), June, 329–330

Price WA, Giannini AJ, Loiselle RH: Bulimia precipitated by pregnancy (letter). May, 275–276

Putnam FW, Guroff JJ, Silberman EK, Barban L, Post RM: The clinical phenomenology of multiple personality disorder: Review of 100 recent cases. June, 285–293

Quadrino LM see Charney DS

Quitkin F see Harrison W

Quitkin FM see McGrath PJ

Rabin D see Grunhaus L

Rabkin J see Harrison W

Ragan Jr FA, Hite SA, Samuels MS, Carey RE, Daul G, Schuler RE: Extended EMIT-DAU phencyclidine screen. Apr, 194–195

Rager P see Yesavage JA

Ragheb MA, Powell AL: Failure of sulindac to increase serum lithium levels. Jan, 33–34

Rainey Jr JM see Pohl R

Ramirez LF: Review of Brende JO, Parson ER: *Vietnam Veterans: The Road to Recovery.* June, 327

Raskind MA, Risse SC: Antipsychotic drugs and the elderly. May, Suppl, 17–22

Reardon G see Rifkin A

Reardon GT see Siris SG

Reese WG see McMillan DE

Regan NJ see Carey Jr RJ

Reich J: DSM-III diagnoses in social security disability applicants referred for psychiatric evaluation. Feb, 81–82

Reich JH, Tookey L: Disagreements between court and psychiatrist on competency to stand trial. Jan, 29–30

Reich T see Zorumski CF

Reifler BV: Mixed cognitive-affective disturbances in the elderly: A new classification. July, 354–356

Remmer HI, Falk WE: Successful treatment of lithium-induced acne (letter). Jan, 48

Renholm G see Rosmark B

Reus V see Zetin M

Reus VI: Review of Baldessarini RJ: *Biomedical Aspects of Depression and Its Treatment.* Jan, 47

Reynolds III CF see Anseau M; Hoch CC

Reznik M see Anseau M

Rice SN: Review of Henao S, Grose N (eds): *Principles of Family Systems in Family Medicine.* Nov, 568

Rich CL: Review of Gunderson JG: *Borderline Personality Disorder.* May, 272

Rich CL, Spiker DG, Jewell SW, Neil JF: Response of energy and suicidal ideation to ECT. Jan, 31–32

Rich CL, Spiker DG, Jewell SW, Neil JF, Phillipson M: ECT response in psychotic versus nonpsychotic unipolar depressives. Mar, 123–125

Rifkin A: Depressive symptoms in acute schizophrenic inpatients (letter with reply). June, 392. See also **Sirls SG**

Rifkin A, Wortman R, Reardon G, Siris SG: Psychotropic medication in adolescents: A review. Aug, 400–408
Rifkin B see Charney DS
Rimon R, Ahokas A, Ruutiainen J, Halonen P: Myelin basic protein antibodies in catatonic schizophrenia. Jan, 26–28
Rinsky H see Modai I
Risse SC see Raskind MA
Rosen AM, Fox HA: Tests of cognition and their relationship to psychiatric diagnosis and demographic variables. Oct, 495–498
Rosenbaum J see Zusky P
Rosenbaum JF see Beckett A; Spier SA
Rosenthal RH: Review of Blanchard EB, Andrasik F: *Management of Chronic Headaches: A Psychological Approach.* Dec, 609–610
Rosmark B, Berne C, Holmgren S, Lago C, Renholm G, Sohlberg S: Eating disorders in patients with insulin-dependent diabetes mellitus. Nov, 547–550
Rosse RB: Cimetidine and mental status changes (letter). Feb, 99–100
Rosse RB, Allen A, Lux WE: Baclofen treatment in a patient with tardive dystonia. Sept, 474–475
Rubin RT see Lesser IM
Rubinson E see Miller AH
Rutherford JL see Zorumski CF
Ruutiainen J see Rimon R
Sabelli HC, Fawcett J, Gusovsky F, Javaid JJ, Wynn P, Edwards J, Jeffries H, Kravitz H: Clinical studies on the phenylethylamine hypothesis of affective disorder: Urine and blood phenylacetic acid and phenylalanine dietary supplements. Feb, 66–70
Sachs GS, Pollack MH, Brotman AW, Farhadi AM, Gelenberg AJ: Enhancement of ECT benefit by yohimbine. Oct, 508–510
Sakio E see Kitamura T
Sakiad SR see Ereshefsky L
Samuels MS see Ragan Jr FA
Sanchez A see Heinze G
Saran AS: Use or abuse of antiparkinsonian drugs by psychiatric patients. Mar, 130–132
Sarantakos S see Kane JM
Satish P see Keshaven MS
Scharf MB, Hirschowitz J, Zemlan FP, Lichstein M, Woods M: Comparative effects of linibitrol and amitriptyline on sleep efficiency and architecture. Dec, 587–591
Schifano F see Magni G
Schlegel A see Fieve RR; Zetin M
Schless A see Mendels J
Schless AP see Mendels J
Schneck JM: S. Weir Mitchell's early fictional reference to Addison's disease (letter). May, 278
Schuckit MA see Motet-Grigoras CN
Schuckit MA, Bogard B: Intravenous drug use in alcoholics. Nov, 551–554
Schuler RE see Ragan Jr FA
Schultz SC see Munetz MR
Schwab JJ: Review of Pimm JB, Feist JR: *Psychological Risks of Coronary Bypass Surgery.* Apr, 216
Schwartz BD see Burch Jr EA
Schwartz C see Carey Jr RJ
Sebastian JA see Mendels J
Secunda S see Mendels J
Sellers EM see Naranjo CA
Semchyshyn G see Mendels J
Shader RI see Dreyfuss D
Shea V see Murray GB
Shear MK: Pathophysiology of panic: A review of pharmacologic provocative tests and naturalistic monitoring data. June, Suppl, 18–26
Sheeley WF: Axis II character disorders in PTSD (letter with reply). Apr, 217
Shemesh Z see Zohar J
Sherman Y: King Saul as a patient (letter). Nov, 572
Shima S see Kitamura T
Shimamura AP: Review of Kolb B and Whishaw IQ: *Fundamentals of Human Neuropsychology (Second Edition).* Feb, 97
Shulman KI: Review of Pearce JMS: *Dementia: A Clinical Approach.* June, 328
Signer SF: Neuroleptic malignant syndrome (letter). Sept, 483
Silberman EK see Putnam FW
Silberstein C see Miller AH
Silver H: Physical complaints correlate better with depression than do dexamethasone suppression test results. Apr, 179–181
Silwance W: Review of Beitman BD, Klerman GL: *Combining Psychotherapy and Drug Therapy in Clinical Practice.* June, 328
Simpson DM, Foster D: Improvement in organically disturbed behavior with trazodone treatment. Apr, 191–193
Simpson GM see Sramek JJ
Singh VK, Fudenberg HH: Can blood immunocytes be used to study neuropsychiatric disorders? Dec, 592–596
Siris SG: Reply to Blum A: Is postpsychotic depression a primary affective disorder? (letter). Sept, 482–483. See also **Rifkin A**
Siris SG, Rifkin A, Reardon GT, Doddi SR, Strahan A, Hall KS: Stability of the postpsychotic depression syndrome. Feb, 86–88
Small GW: Reply to Wade J, Hachinski V: Revised ischemic score for diagnosing multi-infarct dementia (letter). Aug, 437–438
Smith Jr WF: Postpartum psychosis (letter with reply). June, 331
Smith RE see Nasrallah HA
Sohlberg S see Rosmark B
Sorenson SB, Knight K: Suicide in schizophrenia (letter with reply). Nov, 570
Spier SA, Tesar GE, Rosenbaum JF, Woods SW: Treatment of panic disorder and agoraphobia with clonazepam. May, 238–242
Spigland I see Miller AH
Spiker DG see Rich CL
Spikes DG, Dealy RS, Hanin I, Weiss JC, Kupfer DJ: Treating delusional depressives with amitriptyline. May, 243–246
Sramek JJ, Simpson GM, Morrison RL, Heiser JF: Anticholinergic agents for prophylaxis of neuroleptic-induced dystonic reactions: A prospective study. June, 305–309
Stack JA see Hoch CC
Stangl D see Zimmerman M
Starzynski JM see Hsu LKG
Steele C, Lucas MJ, Tune L: Haloperidol versus thioridazine in the treatment of behavioral symptoms in senile dementia of the Alzheimer's type: Preliminary findings. June, 310–312
Steinbook BM see Dominguez RA
Stern TA see Brotman AW
Sternberg DE: Testing for physical illness in psychiatric patients. Jan, Suppl, 3–9
Stewart JW see Harrison W; McGrath PJ
Stewart MA: Review of Bloomingdale LM (ed): *Attention Deficit Disorder—Identification, Course and Rationale.* May, 274
Stojek A, Bilikiewicz A, Napierala K: Physostigmine in alcohol withdrawal: A new clinical approach (letter). Oct, 530
Strahan A see Siris SG
Strawn SK see Evans DL
Strober M see Koehler-Troy C
Sudak HS: Review of Kaslow FW and Ridenour RI (eds): *The Military Family.* Mar, 152
Sulser F: Update on neuroreceptor mechanisms and their implication for the pharmacotherapy of affective disorders. Oct, Suppl, 13–18
Surawicz FG: Review of Lorber J: *Women Physicians: Careers, Status and Power.* Dec, 610
Tan TL see Asadbali JA
Tanke E see Yesavage JA
Tasini M: Complex partial seizures in a patient receiving trazodone. June, 318–319
Taylor RJ see Mendels J
Tesar GE see Spier SA; Woods SW
Thomas MR see Thompson II TL
Thompson II TL, Thomas MR: Depression: Medical interface with psychiatry and treatment advances. Oct, Suppl, 31–36
Thornton JE see Peabody CA
Tilkian SM see Allen AD
Tingle D: Trazodone in dementia (letter). Sept, 482
Tinklenberg JR see Peabody CA
Tondo L: Review of Mavissakalian M, Turner SM, Michelson L (eds): *Obsessive-Compulsive Disorder.* May, 273
Tookey L see Reich JH
Traskman-Bendz L see Asberg M
Tricamo E see Harrison W
Tunson VB: A comparison of parenteral loxapine and haloperidol in hostile and aggressive acutely schizophrenic patients. Mar, 126–129
Tune L see Jayaram G; Steele C
Turner R see Kronfol Z
Tuters K: Review of Slipp S: *Object Relations: A Dynamic Bridge Between Individual and Family Treatment.* June, 327–328
Uhde TW see Joffe RT
Van Peteghem PH see Van Sweden B
Van Putten T, Marder SR: Low-dose treatment strategies. May, Suppl, 12–16
Van Sweden B, Van Peteghem PH: Psychopathology in paraneoplastic encephalopathy: an electroclinical observation. May, 267–268
Van Valkenburg C: Review of Smart RG, Cappell HD, Glaser FB, et al (eds): *Research Advances in Alcohol and Drug Problems.* Feb, 96–97
Varghese FT: ECT in delusionally depressed patients (letter). Apr, 219
Varney N see Nasrallah HA
Versiani M: Review of Tuma AH, Maser JD (eds): *Anxiety and the Anxiety Disorders.* Oct, 527–528
Vital-Herne J, Gerbino L, Kay SR, Katz IR, Opler LA: Mesoridazine and thioridazine: Clinical effects and blood levels in refractory schizophrenics. July, 375–379
Wade J, Hachinski V: Revised ischemic score for diagnosing multi-infarct dementia (letter with reply). Aug, 437
Wager S see McGrath PJ
Wagner A see Asberg M
Wagner RL see Weber SS
Wall M, Mielke D, Luther J: Panic attacks and psychomotor seizures following right temple lobectomy (letter). Apr, 219
Wallis KC: Review of Masterson JF: *The Real Self—A Developmental, Self, and Object Relations Approach.* Dec, 609
Walls PD: Persistent abdominal complaints after discontinuation of phenothiazines (letter). Jan, 48–49
Walter-Ryan WG see Andrews E; Parker PE
Weber SS, Wagner RL: Behavioral changes following generic thioridazine (letter). May, 277–278
Weddington Jr WW, Banner A: Organic affective syndrome associated wtih metoclopramide: Case report. Apr, 208–209
Weller MA, Jobe TH, Nasr SJ, Pandey G, Altman E: 4 p.m. baseline cortisol level as a predictor of DST results in depression. Feb, 60–62
Weintraub RJ see Askinazi C
Weiss JC see Spiker DG
Weiss KJ: Psychostimulants and schizophrenic relapse (letter), Jan, 48; Reply to Zohar J, Insel TR: Obsessive-compulsive disorder and alcoholism (letter), May, 153. See also **Dubin WR**
Weissman MM, Merikangas KR: The epidemiology of anxiety and panic disorders: An update. June, Suppl, 11–17
Wells LA see Hughes PL
White J see White K
White K see Dilsaver SC
White K, White J: Tranylcypromine: Patterns and predictors of response. July, 380–382
Whyte A see Mendels J
Wilcox CS see Cohn JB
Wilson III DC see Casat CD
Wilson LG see Dunner DL
Winokur G see Black DW; Kronfol Z

Woerner M see Kane JM
Wolf JM: Elevated blood neutrophil concentration in mania (letter with reply). June, 331
Woods M see Scharf MB
Woods SW see Charney DS; Spier SA
Woods SW, Tesar GE, Murray GB, Cassem NH: Psychostimulant treatment of depressive disorders secondary to medical illness. Jan, 12–15
Wortman R see Rifkin A
Wynn P see Sabelli HC
Yager J: Bethanechol chloride can reverse erectile and ejaculatory dysfunction induced by tricyclic antidepressants and mazindol: Case report. Apr, 210–211
Yassa R: A case of lithium-chlorpromazine interaction. Feb, 90–91
Yeragani VK see Grover D; Pohl R
Yesavage JA: Psychotropic blood levels: A guide to clinical response. Sept, Suppl, 16–19
Yesavage JA, Benezech M, Larrieu-Arguille R, Bourgeois M, Tanke E, Rager P, Mills M: Recidivism of the criminally insane in France: A 22-year follow-up. Sept, 465–466
Zemlan FP see Scharf MB
Zengotita HE, Holt RJ: Neuroleptic drug-induced coagulopathy: Mechanism of reaction and duration of effect. Jan, 35–37
Zetin M, Garber D, De Antonio M, Schlegel A, Feureisen S, Fleve R, Jewett C, Reus V, Huey LY: Prediction of lithium dose: A mathematical alternative to the test-dose method. Apr, 175–178
Zimmerman M, Pfohl B, Stangl D, Corenthal C: Assessment of DSM-III personality disorders: The importance of interviewing an informant. May, 261–263
Zohar J, Insel TR: Obsessive-compulsive disorder and alcoholism (letter with reply). Mar, 153
Zohar J, Shemesh Z, Belmaker RH: Utility of neuroleptic blood levels in the treatment of acute psychosis. Dec, 600–603
Zorumski CF, Rutherford JL, Burke WJ, Reich T: ECT in primary and secondary depression. June, 298–300
Zusky P, Manschreck TC, Blanchard C, Rosenbaum J, Elliot C, Lou I': Dothiepin hydrochloride: Treatment efficacy and safety. Oct, 504–507